COVER PAGE  
CLINICAL ST UDY PROTOCOL  
 
Study ALA -AK-CT01 8 
[STUDY_ID_REMOVED]  
 
A non -randomized, open -label, multicenter study to evaluate the safety  and tolerability of       
BF-200 ALA (Ameluz®) in the expanded field -directed  treatment of actinic keratosis on the 
face and scalp with photodynamic  therapy (PDT)  
  
Clinical Study 
Protocol
 
 
 
2
1
-
Apr
-
2022
 
ALA
-
AK
-
CT01
8
 
 
Amended 
Version 
3
.0
 
 
 
Biofrontera Bioscience GmbH 
–
 
C
onfidential
 
 
page 
1
 
of 
78
 
TITLE 
P
AGE
 
CLINICAL STUDY 
PROTOCOL
 
 
A 
non
-
randomized, 
open
-
label, multicenter study to evaluate the safety 
and tolerability 
of BF
-
200 ALA (Ameluz
®
) in the 
ex
panded
 
field
-
directed 
treatment of actinic keratosis 
on the face and scalp with photodynamic therapy (PDT)
 
Amended 
V
ersion
 
3
.0
 
ALA
-
AK
-
CT
01
8
 
 
 
Test Product:
 
BF
-
200 ALA (Ameluz
®
)
 
[in combination with 
BF
-
RhodoLED
®
 
XL
]
 
Indication:
 
Mild to 
severe
 
actinic keratosis
 
Study Design:
 
Non
-
randomized, 
open
-
label
, multicente
r
 
Study Identifier:
 
ALA
-
AK
-
CT01
8
 
Study Phase:
 
I
 
Coordinating
 
i
nvestigator:
 
Todd Schlesinger
, MD
 
Clinical Research Center of the Carolinas
 
1364 Ashley River Road
 
Charleston, SC 29407, USA
 
Sponsor:
 
Biofrontera 
Bioscience GmbH
 
Hemmelrather Weg 201
 
51377 Leverkusen, German
y
 
Sponsor’s Signatory:
 
 
Biofrontera Bioscience GmbH
 
Hemmelrather Weg 201
 
51377 Leverkusen, Germany
 
e
-
mail: 
 
Tel.: 
 
Fax: 
 
 
Date of issue
 
2
1
-
Apr
-
20
2
2
 
 
 
The study is designed in accordance with the International Council for 
 
Harmonisation guideline for Good Clinical Practice (ICH
-
GCP E6).
 

Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 2 of 78  DECLARATIONS OF SPONSOR AND INVESTIGATOR S 
DECLARATION OF SPONS OR AND COORDINATING INVESTI GATOR  
This clinical study protocol was subject to critical review and has been approved by the 
sponsor. The information it contains is consistent with:  
• the current risk -benefit evaluation of the investigational product  in conjunction wi th 
an investigational device (combination product)  
• the moral, ethical, and scientific principles governing clinical research as set out in 
the current version of the Declaration of Helsinki, the principles of ICH GCP E6, 
and the provisions of the applicable local law(s) and regulation(s).  
 
The investigator will be supplied with details of any significant or new findings, e.g. 
unexpected serious suspected adverse reaction s /unanticipated serious adverse device effect s, 
related to treatment with the investigational product s. 
 
Sponsor  
Date:  __________  Signature:  ______________________________________  
  Name (block letters):  ______________________________  
 
Coordinating investigator  
Date:  __________  Signature:  ______________________________________  
  Name (block letters):  ______________________________  
  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 3 of 78  DECLARATION OF INVES TIGATOR  
I will work in accordance with the  moral, ethical, and scientific principles governing clinical 
research as set out in the current version of the  Declaration of Helsinki , and the International 
Council for  Harmonisation guideline for G ood C linical P ractice [ICH  E6].  
I will work according to the applicable local law(s) and regulation(s) . 
I confirm that I have read the protocol. I understand it , and I agree that it contains all the 
information required to conduct the study. I agree to conduct the study as set out in thi s 
protocol . I do not deviate from it without prior discussi on with the sponsor except where 
necessary to eliminate an immediate hazard(s) to trial subjects, or when the change(s) 
involves only logistical or administrative aspects of the trial (e.g. change of telephone number(s) ). If I become aware of any protocol deviation, I will communicate details to a 
representative of the sponsor. 
 
Date:  __________  Signature:  ______________________________________  
  Name (block letters):  ______________________________  
 
 
  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 4 of 78  DECLARATION OF BIOSTATISTICIAN 
The undersigned hereby declares his /her consent to the statistical part of the clinical trial 
protocol which is in compliance to current ICH guidelines.  
 
Date:   Signature:  ______________________________________  
  Name (block letters):  ______________________________  
  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 5 of 78  1 TABLE OF CONTENTS  
 
Title page  ............................................................................................................................... 1 
Declarations of sponsor and investigators  .......................................................................... 2 
Declaration of sponsor and coordinating investigator  ...................................................... 2 
Declaration of investigator ................................................................................................... 3 
Declaration of biostatistician  ............................................................................................... 4 
1 Table of contents  ............................................................................................................ 5 
2 Protocol outline  .............................................................................................................. 9 
3 Abbrevia tions and definitions  .................................................................................... 17 
4 Introduction and study rationale  ............................................................................... 20 
4.1 Introduction ................................................................................................................ 20 
4.2 Study rationale  ........................................................................................................... 21 
4.3 Risk/benefit analysis  .................................................................................................. 22 
5 Study objectives  ........................................................................................................... 24 
5.1 Study objective  ........................................................................................................... 24 
6 Study design, duration and dates  ............................................................................... 25 
6.1 Study design ............................................................................................................... 25 
6.2 Study duration, dates and end- of-study definition  ..................................................... 26 
6.3 Definitions  .................................................................................................................. 26 
7 Selection of subjects  .................................................................................................... 27 
7.1 Number of subjects  .................................................................................................... 27 
7.2 Recruitment arrangements  ......................................................................................... 27 
7.3 Inclusion criteria  ........................................................................................................ 27 
7.4 Exclusion criteria  ....................................................................................................... 28 
7.5 Screening failures  ....................................................................................................... 29 
7.6 Subjects of reproductive potential  .............................................................................. 29 
8 Study treatment  ........................................................................................................... 31 
8.1 Details of investigational products  ............................................................................. 31 
 Investigational Medicinal Products  ....................................................................... 31 
 Investigational Medical Device  ............................................................................ 31 
8.2 Storage  ....................................................................................................................... 33 
8.3 Application of BF -200 ALA  ...................................................................................... 33 
8.4 Illumination with BF -RhodoLED® XL ...................................................................... 34 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 6 of 78  8.5 Dosage schedule  ......................................................................................................... 35 
8.6 Treatment assignment  ................................................................................................ 35 
8.7 Blinding, packaging, and labeling .............................................................................. 36 
 Investigational medicinal product  ......................................................................... 36 
 Investigational medical device  .............................................................................. 36 
8.8 Supplies and accountability  ....................................................................................... 37 
8.9 Compliance  ................................................................................................................ 37 
9 Prior and concomitant Medical conditions and treatments  .................................... 38 
9.1 Prior and concomitant medical conditions  ................................................................. 38 
 Medical skin history  .............................................................................................. 38 
9.2 Prior and concomitant medications/treatments  .......................................................... 38 
10 Study procedures and schedule  .................................................................................. 42 
10.1  Description of study days  ........................................................................................... 42 
 Screening visit (≤  14 days prior to PDT)  ............................................................ 42 
 Visit 2/ Baseline/ Treatment (PDT)  .................................................................... 43 
 Visit 3 Safety Interim Visit (7 (± 2) days post PDT)  .......................................... 44 
 Visit 4 Safety Interim Visit (14 (± 2) days post PDT)  ........................................ 44 
 Visit 5 Final Visit (28 (± 7) day post PDT)  ......................................................... 44 
 Unscheduled visit  ................................................................................................ 45 
10.2  Assessments ............................................................................................................... 45 
 Evaluation of demographic data  .......................................................................... 45 
 Body measures  .................................................................................................... 45 
 Clinical criteria for diagnosis of AK  ................................................................... 45 
 Assessment of AK target lesions and documentation of new lesions  ................. 46 
 Biopsy  .................................................................................................................. 46 
 Assessment of skin type  ...................................................................................... 46 
 Safety  ................................................................................................................... 47 
11 Adverse events  ............................................................................................................. 51 
11.1  Definitions  .................................................................................................................. 51 
 Adverse events  .................................................................................................... 51 
 Serious adverse events  ........................................................................................ 52 
 Alert terms and other reasons for expedited reporting to Pharmacovigilance  .... 53 
 Investigational medicinal product complaints  ..................................................... 53 
 Investigational medical device complaints  ......................................................... 53 
11.2  Period of AE collection  .............................................................................................. 53 
11.3  Documentation and reporting of adverse events by investigator  ............................... 53 
 Immediate reporting  ............................................................................................ 55 
11.3.1.1  Reporting of SAEs to sponsor  ..................................................................... 55 
11.3.1.2  Reporting of pregnancies to sponsor  ........................................................... 56 
11.3.1.3  Reporting of USADEs to the sponsor and to IRB  ....................................... 56 
11.3.1.4  Expedited reporting of adverse events to IRB  ............................................. 57 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 7 of 78  
 Unblinding ........................................................................................................... 57 
11.4  Documentation and reporting of adverse events by sponsor  ..................................... 57 
 Determination of expectedness, Reference Safety Information  .......................... 57 
 Expedited reporting  of adverse events to competent authorities and investigators
 57 
 Periodic reporting of adverse events by sponsor  ................................................. 58 
11.4.3.1  Development safety update report (DSUR)  ................................................. 58 
11.5  Continuous risk assessment  ....................................................................................... 58 
12 Withdrawals  ................................................................................................................. 58 
12.1  Withdrawal of subjects  ............................................................................................... 58 
12.2  Replacement of subjects  ............................................................................................. 59 
12.3  Withdrawal of samples  ............................................................................................... 59 
13 Emergency procedures  ............................................................................................... 60 
13.1  Emergency sponsor contact  ....................................................................................... 60 
13.2  Emergency identification of investigational medicinal products  ............................... 60 
13.3  Emergency treatment  ................................................................................................. 60 
14 Statistical procedures  .................................................................................................. 61 
14.1  General considerations  ............................................................................................... 61 
14.2  Analysis variables  ...................................................................................................... 61 
14.3  Analysis sets  ............................................................................................................... 62 
14.4  Statistical methods  ..................................................................................................... 62 
 Disposition of subjects and exposure  .................................................................. 62 
 Demographics and background characteristics  ................................................... 62 
 Evaluation of the Safety Endpoints  ..................................................................... 62 
14.5  Handling of missing data  ........................................................................................... 64 
14.6  Interim analysis  .......................................................................................................... 64 
14.7  Sample size justification  ............................................................................................ 64 
14.8  Major Protocol Deviations  ......................................................................................... 64 
15 Ethical and legal aspects  ............................................................................................. 65 
15.1  Good clinical practice  ................................................................................................ 65 
15.2  Delegation of investigator duties  ............................................................................... 65 
15.3  Subject information, informed consent and HIPAA form  ......................................... 65 
15.4  Confidentiality  ........................................................................................................... 65 
15.5  Protocol deviations  ..................................................................................................... 66 
15.6  Protocol amendments  ................................................................................................. 66 
15.7  Approval of the clinical study protocol and amendments  .......................................... 66 
15.8  Ongoing information for ethics committee/institutional review board  ...................... 67 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 8 of 78  15.9  Closure of the study  ................................................................................................... 67 
15.10  Record retention  ......................................................................................................... 67 
15.11  Liabilit y and insurance  ............................................................................................... 67 
15.12  Financial disclosure  .................................................................................................... 68 
16 Quality control, quality assurance, and inspections ................................................. 69 
16.1  Study monitoring and source data verification  .......................................................... 69 
16.2  Site audits  ................................................................................................................... 69 
16.3  Site Inspections  .......................................................................................................... 69 
17 Documentation and use of study findings  ................................................................. 70 
17.1  Documentation of study findings  ............................................................................... 70 
17.2  Use of study findings  ................................................................................................. 70 
18   References  .................................................................................................................... 72 
19 Appendices  ................................................................................................................... 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 9 of 78  2 PROTOCOL OUTLINE  
Title  
A non-rand omized, open -label, multicenter study to evaluate the safety and tolerability 
of BF -200 ALA (Ameluz®) in the ex panded field -directed treatment of actinic keratosis 
on the face and sca lp with photodynamic therapy (PDT)  
Study no: ALA -AK-CT01 8 Clinical Phase: I  
Study Design 
This is a  non- randomized, open- label , multicenter study to evaluate the safety and 
tolerability of BF-200 ALA in the treatment of actinic keratosis ( AK) located on the face and 
scalp with  photodynamic therapy ( PDT) when using the BF -RhodoLED® XL lamp. Each 
subject will receive the content of 3 tubes  (6 g) of BF -200 ALA  for an ex panded field -
directed treatment.  
Investigators / study sites  
Approximately 10 sites in the United States of America (US) will participate in this study. 
Each site should dose  between 5 and 15 subjects. No site should dose more than 20 subjects 
unless prior approval of the sponsor is obtained. The maximum number should in no case exceed 25 subjects.  
Number of subjects  
It is planned to dose approximately 100 subjects.  
Subjects and lesions  
Subjects with mild to severe AK (according to Olsen et al.,1991) of all sexes and of age 18 years and older will be enrolled. 
Presence of at least 8 mild to moderate  (Olsen et al., 1991)) clinicall y confirmed AK lesions  
with a diameter ≥  4 mm with in a treatment fie ld on the face and/or scalp. In addition, s evere 
AK lesions may be present in the treatment field . In case of severe AK lesions, a biopsy must 
be taken for confirmation of diagnosis . The treatment field may be continuous or in  several 
patches , totaling about  60 cm² in  each subject and must be located within one effective 
illumination area . 
Definitions  
• “illumination area” is the area effectively illuminated by one BF -RhodoLED® XL lamp  
in one illumination session  
• “treatment field” is the part  of the  skin to which IMP is applied 
• “treatment area” describes a region of the body in which the treatment field is located, 
distinguishing between face ( including forehead, excluding eyes, nostrils, and mouth) 
and scalp  (bald scalp, excluding ears ) 
• “target lesions” are all AK lesions (mild  to severe)  located within the treatment field  
Investigational product s (IP)    
Investigational medicinal product (IMP)  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 10 of 78  BF-200 ALA.  
BF-200 ALA is a gel formulation of 10 % 5 -aminolevulinic acid hydrochloride , 
corresponding to 7.8 %  5-aminolevulinic acid (ALA) . It is approved as Ameluz® by the 
Food and Drug Administration (FDA)  in combination with photodynamic therapy using BF-
RhodoLED® lamp  and indicated  for the lesion -directed and field -directed treatment of 
actinic keratoses (AK) of mild to moderate severity on the face and scalp. The IMP will be 
packed in tubes, containing 2 g each.  Three tubes will be applied per subject . 
Investigational medical devic e (IMD)  
The study treatment requires illumination of the treatment field with ~37  J/cm² of red -light at 
~635 nm. Approved for PDT in combination with Ameluz® is the BF -RhodoLED® lamp. In 
this study, t he BF -RhodoLED® XL will be used which allows the illumination of a larger 
area than the BF -RhodoLED®.  
Study Duration and Dates  
Each subject will be in the study for  approx. 6 weeks. 
Within 14 days  after the screening visit (Visit 1) and following confirmation of eligibility, 
subjects will be treated with PDT (Visit 2). At Visit 3 (7 days post PDT) and Visit 4 (14 days post PDT) assessment of  transient side effects will be performed . At Visit 5, 28 days  post  
PDT, the  final evaluation of safety and tole rability will be performed.  
In-/exclusion criteria  
 Inclusion criteria  
 
1. Willingness and ability of  subject s to provide informed consent and sign the Health 
Insurance Portability and Accountability Act (HIPAA) form. A study -specific 
informed consent and HIPAA form must be obtained in writing prior to starting any study procedures. 
2. Subjects with mild to severe clinically confirmed AK lesions (according to Olsen (Olsen et al., 1991)) on the face and/or scalp. In case of severe AK lesions, a biopsy 
must be taken for confirmation of diagnosis. At least 8 mild to moderate AK lesions with a diameter of  ≥4 m m must be present in the treatment field. The  treatment field 
(continuous or in  several patches ) totaling about  60 cm
2 must  be located within one 
effective illumination area.  The AK  lesions should be clearly distinguishable, without 
restrictions on the distance between lesions. Lesions should have a  minimal distance 
of 1 cm between the lesion margin and the border of the treatment field . 
3. All sexes , ≥18 years of age . 
4. Willingness and ability to comply with study procedures, particularly willingness to receive a PDT  session  and to undergo 2 mm punch biops y/biopsies in case of severe 
AK lesion (s) at the screening visit. 
5. Subjects with good general health or with clinically  stable medical conditions will be 
permitted to be included in the study. Subjects with clinically stable medical conditions will be permitted for inclu sion into the study if not using prohibited 
medication.   
6. Willingness to stop the use of moisturizers and  any other non- medical topical 
treatments within the treatment field at least 24  h prior to the visits . 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 11 of 78  7. Acceptance to abstain from extensive sunbathing and the use of a solarium  or tanning 
beds during the  study .  
8. For female subject s with reproductive potential: Negative serum pregnancy test.  
9. For female subject s with reproductive potential: Effective contraception at screening 
visit and t hroughout the study . 
 
Exclusion criteria  
1. Any known history of hypersensitivity to ALA, porphyrins or excipients of BF -200 
ALA.  
2. History of soy or peanut allergy.  
3. Subjects with sunburn or other possible confounding skin conditions (e.g. wounds, 
irritations, bleeding or skin infections) inside  or in close proximity (<  10 cm distance) 
to the treatment field.  
4. Clinically significa nt (CS) medical conditions making implementation of the protocol 
or interpretation of the study results difficult or impairing subject’s safety such as: 
a. Presence of photodermatoses or porphyria  
b. Metastatic tumor or tumor with high probability of metastasis  
c. Infiltrating skin neoplasia (suspected or known)  
d. Unstable cardiovascular disease (New York Heart Association class III, IV)  
e. Unstable hematologic (including m yelodysplastic syndrome), hepatic, renal, 
neurologic, or endocrine condition  
f. Unstable collagen -vascular condition 
g. Unstable gastrointestinal condition  
h. Immunosuppressive condition  
i. Presence of clinically significant inherited or acquired coagulation defect  
5. Clinical diagnosis of atopic dermatitis, Bowen’s disease,  basal cell carcinoma,  
eczema, psoriasis, rosacea, squamous cell carcinoma, other malignant or  benign 
tumors inside  or in close proximity (<  10 cm distance) to the treatment field.  
6. Presence of strong artificial pigmentation  (e.g. tattoos ) or any other abnormality that 
may impact lesion assessment or light penetration in the treatment field.  
7. Any physical therapy such as cryo surgery , laser therapy, electrodessication, 
microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside or in close proximity (< 10 cm distance) to the treatment field within 4 weeks prior to screening.  
8. Any of the  topical treatments  defined below  within the designated periods  prior to 
screening:   
a. Topical treatment with ALA or ALA esters (e.g. methyl aminolevulinic acid (MAL)) or an investigational drug in-  and outside the treatment field within 8 
weeks.  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 12 of 78  b. Topical treatment with immunosuppressive , cytostatic or  cytotoxic drugs 
inside or in close proximity (< 10 cm distance) to the treatment field within 8 
weeks . 
c. Start of topical administration  of a medication with hypericin or other  drugs 
with phototoxic or photoallergic potential  inside or in close proximity (< 10 
cm distance) to the treatment field within 4 weeks . Subjects may, however, be 
eligible if such medication was applied for more than 4 weeks prior to 
screening without evidence of an actual phototoxic/photoallergic reaction.  
9. Any use of the systemic  treatments  within the designated periods  prior to screening : 
a. Cytostatic or cytotoxic drugs within 6 months . 
b. Immunosuppressive therapies or use of ALA or ALA  esters (e.g. MAL) 
within 12 weeks . 
c. Drugs known to have major organ toxicity within 8 weeks  or an 
investigational drug.  
d. Interferon or glucocorticosteroids within 6 weeks.  
e. Start of intake of medication with hypericin or systemically acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening. Subjects may, however, be  eligible if such medication was taken in for more 
than 8 weeks prior to t he sc reening visit without evidence of an actual 
phototoxic/photoallergic reaction.  
10. Breast feeding women.  
11. Suspicion of drug or alcohol abuse.  
12. Subject s unlikely to comply with protocol, e.g. inability to return for visits, unlikely to 
complete the study, or ina ppropriate in the opinion of the investigator.  
13. A member of study site staff or sponsor staff directly involved in the conduct of the protocol or a close relative thereof.  
14. Simultaneous participation in another  clinical study . 
Re-screening  of subjects is allowed once in case exclusion criteri on 3 is  met and eligibility 
can be achieved within 14 days .  
 
Dosing day exclusion criteria  
At Visit 2 (baseline, PDT -1) 
Subjects with sunburn or other possibly confounding skin conditions (e.g. wounds, irritations, bleeding or skin infections) inside or in close proximity (<  10 cm distance) to the 
treatment field. Re -assessment of subjects is allowed within 14 days  once the sunburn or 
other confounding skin conditions is/are expected to resolve.  
Treatment  
Subjects will be treated with  PDT applying BF -200 ALA (Ameluz®). The IMP is packed in 
tubes, each containing 2 g gel. A pack of 3 tubes will be assigned to each subject to allow 
treatment with 3 tubes for PDT. For the PDT, the content of al l 3 tubes wil l be 
homogenously applied as an ~1 mm thick layer to the assigned  treatment field 
(approximately 60 cm²).  
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 13 of 78  The treatment field should be prepared for IMP application by degreasing (using ethanol or 
isopropanol) and removal of scabs and crusts, and if appropriate roughening of the surface, 
(e.g. by mild debridement). Care  should be taken to avoid bleeding. The IMP (3 tubes á 2 g 
of BF -200 ALA) will then be applied to the entire treatment field,  including all AK target 
lesions. All AK target lesions should have a minimal distance of 1 cm to the border of the treatment field . The study medication will be allowed to dry and subsequently covered with a 
light- blocking, occlusive dressing for approx. 3 h. Thereafter, the occlusive dressing and any 
remnants of the applied study medication will be removed and a 10 min illumination with approx. 37 J/cm
2 will be administered using the red -light LED device BF -RhodoLED® XL. 
Study  objective  
The objective of the study is to evaluate the safety and tolerability of BF -200 ALA PDT, 
utilizing BF -RhodoLED® XL illumination, in the treatment of mild to severe actinic 
keratosis on the face and scalp  in an ex panded field -directed treatment . 
The endpoints of the study are:  
• Frequency and severity  of adverse events (AEs), serious AEs (SAEs), and treatment -
emergent adverse events (TEAEs). TEAEs are defined as all AEs with onset or 
worsening after treatment with IMP  up to Visit 5  
• Duration of TEAEs including the breakdown of severity category (mild, m oderate, 
severe)  
• Assessment of new lesions (AK, non- melanoma skin cancer [NMSC] such as BCC, 
SCC or Bowens disease , and melanoma) if they occur inside the treatment field  
• Assessment of new lesions (AK, NMSC , and melanoma) if they occur around the 
treatment field at a distance of < 10  cm 
• Application site skin reactions during and post PDT , assessed by the investigator  
• Application site discomfort during and post PDT , reported by the subjects  
• Application site pa in during illumination, as assessed  by the subjects using  an 11-
point numeric rating scale  
• Changes in vital signs  
• Safety laboratory data  
• Physical examination data  
• Neurological assessments  
Sample size calculation  
Not applicable  
Statistics  
Endpoints will be analyzed using the safety analysis dataset (SAF)  and analyzed 
descriptively and in an exploratory way . 
Clinical Study Protocol    21-Apr-2022 
ALA- AK-CT01 8  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – C onfidential   page 14 of 78  Schedule  - study overview  
 
 

Clinical Study Protocol  21-Apr-2022 
ALA -AK-CT018  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential  page 15 of 78 
 Table 1 Study schedule  
 Visit  1 Visit  2 Visit 3  Visit 4  Visit  5 
 Screening  PDT  Safety Interim Visit  Safety Interim Visit  Final Visit  
 ≤ 14 days  
prior to PDT  Baseline/ treatment  7 days  
(± 2 days)  
post PDT  14 days  
(± 2 days)  
post PDT  28 days  
(± 7 days ) 
post PDT  
Clinical visit * X X X X X 
Obtain Informed consent  X     
Assignment of subject number  X     
Demographics  X     
Inclusion/exclusion criteria  X Xa    
Dosing day  exclusion criterion   Xb    
Relevant medical history (excluding medical skin 
history) / concomitant medical conditions  X     
Medical skin history  X     
Skin type assessment  Xc     
Body measures  X     
Vital signs  X Xd X X X 
Physical examination  X    X 
Neurological assessments  X Xe    
Selection of the treatment field and assessment of AK 
target lesions (size, number, location, and severity)  Xf     
Generation of templates (Grid foil, cartoon) for re -
identification of AK lesions inside or in close 
proximity (< 10 cm distance) to the treatment field  X     
Skin assessment regarding new  lesions (AK, NMSC 
and melanoma) inside or in close proximity (< 10 cm 
distance) to the treatment field g  X X X X 
Clinical laboratory testsh including serum pregnancy 
test, if applicable  i X    X 
Urine pregnancy test i  X    
Clinical Study Protocol  21-Apr-2022 
ALA -AK-CT018  Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential  page 16 of 78 
  Visit  1 Visit  2 Visit 3  Visit 4  Visit  5 
 Screening  PDT  Safety Interim Visit  Safety Interim Visit  Final Visit  
 ≤ 14 days  
prior to PDT  Baseline/ treatment  7 days  
(± 2 days)  
post PDT  14 days  
(± 2 days)  
post PDT  28 days  
(± 7 days ) 
post PDT  
Explanation of allowed/ forbidden medication before and after PDT to subjects  X X    
Inform subjects about restrictions to sunlight, 
prolonged or intense light  for 48 h after IMP 
application   X   
 
Explanation and handout of subject diary   X    
Collection of subject diary      X 
Field -directed application of IMP and illumination 
(including preparation of the treatment field)   X    
Assessment of application site pain during illumination 
via NRS -11   X    
(S)AEs   X Xj X X X 
Concomitant medications/ treatments  X X X X X 
(S)AE: (Serious) Adverse Event; AK: Actinic Keratosis; ALA: 5 -aminolevulinic acid; BP: Blood Pressure; HR: Heart Rate; IMP: Investigational medicinal product; NMSC: Non -melanoma skin cancer; NRS: 11 -point Numeric Rating Scale; PDT: 
Photodynamic Therapy  
a Re -check of eligibility.  
b Visit 2 can be rescheduled within 2 weeks after the scheduled date if the dosing day exclusion criterion is met  
c Skin type will be evaluated according to Fitzpatrick criteria (Fitzpatrick 1988).  
d Vital signs will be measured after th e subject arrived at the site and will be additionally assessed within 10 min before start of illumination, within 10 min after end of illumination and 60 (±10) min after end of illuminatio n 
e Neurological assessments will be done prior to PDT and 60 (±10)  min after end of illumination  
f Lesions will be evaluated according to Olsen criteria ( Olsen et al., 1991). Additionally, for severe AK lesions the diagnosis of AK must be confirmed by  histopathological examination of  biops y. 
g Any new AK, NMSC ( such as BCC ,SCC or Bowens’s disease ) and melanoma have to be reported as (S)AEs if they occur inside or in close proximity (< 10 cm distance) to the treatment field.  
h Clinical laboratory tests will include routine hematology, blood chemistry, and urinalysis.  
i All female participants of reproductive potential will undergo a pregnancy test.  
j When the subject arrives at the site, within 10 min after end of illumination and 60 (±10) min after end of illumination  
 
*Unscheduled visit: Unscheduled visits may be performed for safety reasons.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 17 of 78   3 ABBREVIATIONS  AND DEFINITIONS  
β-hCG    Human chorionic gonadotropine  
ADE    Adverse device event  
AE   Adverse event  
AK   Actinic keratosis  
ALA    5-aminolevulinic acid  
ALT    Alanine aminotransferase 
AST    Aspartate aminotransferase 
ATC    Anatomical Therapeutic Chemical Classification System  
BCC    Basal cell carcinoma  
BF   Biofrontera  
BF-200 ALA   Nanoemulsion gel formulation containing 7.8 % ALA  
(development name for Ameluz®) 
BP   Blood pressure  
CI   Confidence interval  
cm   centimeter  
CRO    Contract Research Organization  
CSP   Clinical study protocol  
DSUR    Development safety update report  
eCRF    Electronic case report form  
EDTA    Ethylendiaminetetraacetic acid  
EMA    European Medicines Agency  
Enrolled  A subject is defined as enrolled when informed consent has been given  
EoS   End-of-Study  
EU   European U nion 
FDA    Food and Drug Administration 
g   Gram(s)  
GCP    Good clinical practice  
GGT    Gamma -glutamyl transferase  
GmbH   Gesellschaft mit beschränkter Haftung, Ltd, limited liability company  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 18 of 78   GMP    Good manufacturing practice  
HIPAA  Health Insurance Portability  and Accountability Act  
HR   Heart  rate 
IB   Investigator’s brochure  
ICF   Informed consent form  
ICH International Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
Illumination area  Area which is effectively illuminated by one BF-RhodoLED® XL lamp 
in one illumination session 
IMD  Investigational medical device  
IMP Investigational medicinal product  
IND Investigational New Drug  
IRB Institutional review board  
ISF   Investigator Site File  
LED    Light  emitting diode  
MedDRA   Medical Dictionary for Regulatory Activities  
NMSC    Non-melanoma skin cancer  
NRS -11  Numeric R ating S cale (11 -point pain rating scale)  
NSAID   Non-steroidal  anti-inflammatory drugs  
NYHA    New York Heart Association  
PDT    Photodynamic  therapy  
PI   Prescribing Information  
PpIX    Protoporphyrin IX  
PTAEs    Pre-treatment adverse events  
RSI   Reference safety information  
SAE    Serious adverse event  
SAF   Safety analysis set  
SAP   Statistical analysis plan  
SAR    Serious adverse reaction  
SCC    Squamous cell carcinoma 
SD   Standard deviation  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 19 of 78   SOP   Standard Operating Procedure  
TEAEs    Treatment -emergent adverse events  
Treatment area  Body region  in which the treatment field is located  
Treatment field  Part of the skin to which IMP  is applied  
USADE   Unanticipated serious adverse device effect  
UV   Ultraviolet 
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 20 of 78   4 INTRODUCTION AND STUDY RATIONALE  
4.1 Introduction  
(Solar) actinic keratosis (AK) , also known as squamous cell carcinoma (SCC) in situ , 
represents the most common neoplasia affecting fair -skinned subjects and develops in 
chronically sun- exposed skin areas. It is assumed that AK is the result of the accumulation of 
damage in keratinocytes caused by irradiation with ultraviolet (UV) light. Lesions of different 
sizes are found in affected subjects, ch aracterized by rough, scaly and erythematous patches. 
Epidermal changes can include hyperkeratosis, parakeratosis, dyskeratosis, acanthosis, or keratinocyte atypia. In one prospective study by Czarnecki et al.  (1), 72 % of 208 subjects 
with invasive SCC had AK contiguous to the SCC. It was concluded that the SCC arose i n 
these AK lesions. In addition, epidemiological data have indicated that AK lesions, as an 
indicator for chronic sun damage, are a reliable marker for people who are predisposed to the development of an invasive SCC ( 2). Today, it is generally accepted that AK represents an 
early stage of a malignant condition (carcinoma in situ) that can progress t o SCC  (3,4). 
Between 0.025 % and 16  % of the AK lesions develop into SCC ( 5). Therefore, it wa s highly 
recommended to treat AK lesions before they progres s to skin cancer . This was further 
manifested by several observations which conflicted  with the initially assumed sequence  of 
progression from mild AK lesions to lesions of moderate or severe phenotype and subsequent  
progression to SCC . First,  the clinical  classification of lesions using Olsen grading match es 
the histopathological classification according to Röwert -Huber  or Cockerell only poorly  (6). 
Second, if AKs progress to SCC th ey do this on average within about 24 months after coming 
into existence  (7). Third, SCC arises more frequ ently from mild lesions
 than from more 
serious lesions according to Olsen grading ( 8). 
This observation reinforces the need to also treat AK lesions of mild clinical phenotype and even cancerous fields , as both represent a high risk of progression to SCC .  
Based on these observations , recent guidelines and expert recommendations advise  early and 
field-directed treatment to address all AK severity grades, including subclinical 
manifestations ( 4,9–14) . Photodynamic therapy ( PDT ) with Ameluz
® (BF-200 ALA) in 
combination with the narrow -band BF-RhodoLED® lamp is FDA approved for the  field -
directed  treatment of  mild to moderate AK on the face and scalp .  
BF-200 ALA gel contains 10 % ALA hydrochloride, equivalent to 7.8 % ALA in a 
nanoemulsion formulation and  was shown to improve skin penetration and uptake of ALA in 
the target area due to the lipophilic component of the nanoemulsion ( 15,16) . Thus, as a resul t 
of the better penetration capacities, the amount of ALA in the marketed formulation could be 
reduced to 7.8 %, half of comparable formulations on the market . Furthermore, this 
formulation significantly enhances the shelf -life as well as in -use stability of the active 
ingredient  in an aqueous environment . This is considered a relevant advantage, given the 
instability of ALA in aqueous formulations. 
Ameluz® in combination with the  red-light BF -RhodoLED® lamp has been approved for the 
lesion - and field -directed PDT  of actinic keratoses of mild  to moderate severity on the face 
and scalp by the Food and Drug Administration (FDA) on May 10th, 2016 (NDA 208081).  
In the European Union (EU), t he Eur opean Medici nes Agency (EMA) granted a  centralized  
Marketing Authorization for Ameluz® for the treatment of mild  to moderate AK on the face 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 21 of 78   and scalp in December 2011 (EU/1/11/740/001). In November 2012, the BF-RhodoLED® 
medical device was CE -marked and subsequently l aunched in the European market. In 
September 2016 the approval was extended to the indication of field cancerization, and in 
January 2017 to the treatment of superficial and nodular basal cell carcinoma ( BCC ). In 
March 2018, the EMA granted extension of th e posology to the treatment of mild  to moderate 
AK on the face and scalp and field cancerization with daylight PDT . On March 10, 2020, the 
European marketing authorization was extended to  PDT  treatment of mild to moderate AK on 
the extremities and neck/trunk using narrow spectrum red light , based on a  European P hase III 
study  (ALA -AK-CT010) . 
Ameluz® furthermore received marketing approval in Switzerland for the treatment of mild  to 
moderate AK on the face and scalp with conventional PDT in November 2015 (Swissmedic 
number: 65693)  and for the treatment with daylight PDT in September 2018. Subsequently, 
Swissmedic  approved Ameluz® for t he treatment of field cancerization and BCC in May 2018 
(Swissmedic number: 65693).  
Given that the size  of fields wit h chronic actinic sun damage  frequently  exceeds the usually 
approved area size of 20 -25 cm² ( 17), an open label safety study under maximal use 
conditions was  conducted in the US  additionally . This Phase I trial  (ALA -AK-CT015)  aimed 
at assessing  pharmacokinetic data as well as subjects´ safety and tolerability after a single 
PDT w ith BF -200 ALA  in conjunction with the BF -RhodoLED® applying the content of 3 
tubes  of BF -200 ALA  in subjects with actinic keratosis to an expanded treatment field of 
60 cm² located on the face/scalp or in the periphery  (neck/trunk/extremities).  
The Marketing Authorization Holder (Biofrontera Bioscience GmbH)  now  intends to perform 
a safety stud y in the US to  confirm the safety profile of BF -200 ALA in the treatment of mild 
to severe actinic keratosis  on the face and scalp with PDT when applying the content of 3 
tubes of BF -200 ALA  per PDT  in conjunction with a new medical device, the  BF-
RhodoLED® XL lamp. This lamp allows  the illumination of a larger area  than the BF -
RhodoLED®. 
4.2 Study rationale  
Current FDA -approved tr eatment option s for field -directed treatment  of AK  on the face and 
scalp  are formulation s containing diclofenac/hyaluronic acid (3  %/2.5 %), imiquimod cream 
(3.75%)  or 5-fluoruracil , which require repeated applications for up to several months  or lead 
to side effects rel ated to erosive  and/or inflammatory reactions induced by the treatment that 
may last for the entire treatment period or even longer  (18–20) . 
Compared to  methods like surgery, abrasion, cryosurgery , and alternative topical treatments,  
the use of PDT is advantageous for the field -directed treatment especially due to the high 
selectivity  of treatment , but also to the short treatment period  that is  entirely controlled by the 
physician , and the excellent cosmetic results (21). 
In addition, a European network meta -analysis of the relative clinical  efficacy of 10 different 
treatment modalities for mild to moderate AK on the face and scalp, including PDT products 
as well as formulations containing cryo surgery , 5-fluorouracil, imiquimod, ingenol mebutate 
or diclofenac/ hyaluronic acid, has shown that ALA PDT using BF -200 ALA was the most 
efficacious treatment option  (22). 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 22 of 78   Besides Ameluz®, only one PDT product  containing ALA is  available in the US market. 
Levulan® Kerastick® providing  ALA at a concentration of 20 % in  a 2-component system  that 
requires  ALA to be compounded immediately before use.  By label, the use of Levulan® 
Kerastick® is restricted to  lesion -directed treatment  of minimally to moderately thick AKs 
located on the face and scalp  or the  upper extremities . Ameluz® is the only PDT product 
available in the US market which has been approved for the field -directed treat ment of AKs , 
but at the current time its label is restricted to the application of one tube of Ameluz®. 
In contrast to the currently marketed  BF-RhodoLED® lamp the BF -RhodoLED® XL enables 
the illumination of a larger skin area  in one step. The BF-RhodoLED® XL has 5 LED panels 
which are positioned in a curved shape.  
This safety  study is designed to confirm the safety and tolerability of BF -200 ALA  (Ameluz®) 
in combination with  BF-RhodoLED® XL for the field -directed treatment of mild to severe AK 
located on the face and scalp  in an expanded treatment field of 60 cm², applying the content of 
3 tubes of BF -200 ALA  for PDT . Using the  curved shape configuration of BF -RhodoLED XL 
permits  an even illumination of the entire face or scalp  and facilitates the illumination of  
discontinuous t reatment field in one step.  
4.3 Risk /benefit analysis 
This safety  study will include diseased subject s presenting with at least 8 mild to moderate 
AK lesions  (≥4 mm) within the treatment field  of about 60 cm2 in total.  In addition, severe 
AK l esions may  be present  in the treatment field.  Subje cts will receive BF-200 ALA 
treatment  - already marketed for the treatment of AK in the US, EU , and  Switzerland under 
the brand name Ameluz® - with  conventional red -light illumination .  
Clinical efficacy and safety of BF -200 ALA in combination with conventional red -light 
illumination for the treatment of mild to moderate AK on the face and scalp  were previously 
examined in one  dose -finding study, and three  confirmatory stu dies encompassing a total of 
885 randomized subject s comprising 462 subjects  (2674 lesions) exposed to BF -200 ALA  
(7.8%  ALA) (23–25)  treated on t he face and scalp . All subjects received up to 1 tube ( 2 g) of 
BF-200 ALA . In these pivotal clinical trials, complete response  of subjects 12 weeks after the 
last PDT  with BF -200 ALA was shown to be up to 90.9 %  and total lesion response  was up to 
94.3 %  (23–26) .  
In previous clinical trials with BF -200 ALA , local application si te reactions were observed in 
84-100 % of the subjec ts. These reactions are expected, given the therapeutic principle of 
PDT, which is based on phototoxic effects. The most common signs and symptoms were 
application site erythema , pain /burning , irritation,  and edema. Most adverse reactions 
occur red during illumination or shortly afterwards. S ymptoms were usually of mild or 
moderate intensity (investigator’s assessment on a 4 -point scale ). Subject s treated with a 
higher dose ( 6 g / 3 t ubes BF-200 ALA) within  an enlarged treatment field of 60 cm² 
experienced more  severe application site reactions (mainly pain, erythema) when treated o n 
the face and scalp  which was not reported for subjects treated in the periphery. Given that 
PDT pain was already described to be related to the size of treatment field  (27), a higher pain 
intensity during treatment of an expanded treatment field on the face and /or scalp w as to be 
expected.  Nonetheless , application site pain during PDT i s transient and well manageable.  In 
most cases the symptoms last ed for 1 to 4 days , however , in some cases, they  persist ed for 1 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 23 of 78   to 2 weeks or even longer. It is known that t he intensity of AEs depends  on the applied light 
spectrum used for PDT and correlate s with the higher response  rate achieved by the use of 
narrow spectrum lamps, emitting aro und 630 nm, e.g. BF-RhodoLED®. In rare cases, adverse 
reactions may require interruption or discontinuation of the illumination.   
Common adverse reactions of PDT with BF -200 ALA include headache and reactions at the 
application site, such as erythema, pain/burning, irritation  (burning) , edema, pruritus, 
exfoliation, scab, indur ation, vesicles . More detailed information on known adverse reactions 
is provided in the pres cribing information (PI)  for Ameluz® (28). This drug is contraindicated 
in subject s with known hypersensitivity to ALA, to porphyrins or to any excipients  of 
Ameluz®, and  in subject s with porphyria or photodermatoses.  
It is assumed that local adverse reactions in the present study will be similar to those known 
from treatment of AK lesions as well as cancerous fields described previously . If required , 
pain management will be performed according to established guidelines ( 29,30) but 
restrictions for c o-medication s/treatments  described in this protocol must be taken into 
consideration.  
In this study, inclusion and exclusion criteria have been chosen to minimize possible risks due to the administration of BF -200 ALA , and to ensure  a uniform study popula tion. BF -200 ALA 
and the PDT lamp BF -RhodoLED
® XL will be handled by appropriately trained study 
personnel. The setting of BF-RhodoLED® XL is comparable to BF-RhodoLED® used in t he 
previous studies  such that  the em itted wavelength is 635 nm a nd same light dose of 37 J/cm2 
will be applied.    
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 24 of 78   5 STUDY OBJECTIVES  
5.1 Study  objective  
The objective of the study is to evaluate the safety and tolerability of BF -200 ALA PDT, 
utilizing BF -RhodoLED® XL illumination, in the treatment of mild to severe AK on the face 
and scal p in an ex panded field -directed treatment . 
The endpoints of the study are:  
• Frequency and severity of adverse events (AEs), serious AEs (SAEs), and treatment -
emergent adverse events (TEAEs). TEAEs are defined as all AEs with onset or 
worsening after treatment with IMP  up to Visit 5  
• Duration of TEAEs including the breakdown of severity category (mild, moderate, 
severe)  
• Assessment of new lesions (AK, NMSC such as BCC, SCC or Bowens disease , and 
melanoma) if they occur inside the treatment field  
• Assessment of new lesions (AK, NMSC , and melanoma) if they occur around the 
treatment field at a distance of < 10  cm 
• Application site skin reactions during and post PDT , assessed by the investigator  
• Application site discomfort during and post PDT , reported by the subjects  
• Application site pain during illumination, as assessed  by the subjects using  an 11- point 
numeric rating scale  
• Changes in vital signs  
• Safety laboratory data  
• Physical examination data  
• Neurological assessments  
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 25 of 78   6 STUDY DESIGN, DURATIO N AND DATES  
6.1 Study design  
This protocol describes a multicenter, open label study that will be conducted in the United 
States of America (US). Approximately 10 sites in the US will participate in this study. Each 
site should dose  between 5 and 15 subjects . No sit e should dose  more than 20 subjects unless 
prior approval of the sponsor is obtained. The maximum number should in no case exceed 25 
subjects.   
The clinical study will consist of: 
• a screening visit (within 14 days  before treatment), at which eligibility of subjects for 
study participation will be assessed (Visit 1)  
• a baseline/treatment visit, at which eligible subjects will receive PDT with application 
of the content of  3 tubes of BF -200 ALA (Visit 2)  
• two interim visits  for safety assessment  7 days  (± 2 days ) (Visit 3) and 14 days (± 2 
days)  (Visit 4)  post PDT  
• a final  clinic  visit, 28 (± 7) days  post PDT , at which safety and tolerability assessments 
will be performed (Visit 5)  
Figure 1 illustrates treatment details on study visits. An overview of scheduled assessments is 
provided in Table 1.  
 
 
* Visit 2 can be rescheduled once within 14 days  after the scheduled date if  the dosing day exclusion criterion 
(sunburn or other possible confounding skin conditions inside  or in close proximity (<  10 cm distance) to the 
treatment field ) is met and if the sunburn or other confounding skin conditions is/are expected to resolve within 
14 days . 
Figure 1 : Summary of study visits  
 
The PDT procedure  (preparation of treatment field , drug application, incubation, illumination ) 
will be performed  similar  to the prescribing information of Ameluz® (28). Details will be 
described in S ection  8.  

Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 26 of 78   6.2 Study duration, dates and end -of-study definition  
For each subject the duration of the study is expected to be approx. 6 weeks . The overall study 
duration is estimated to be about 6.5 months (including an approx. 5-month recruitment  
phase ). The duration of the overall study or the subject recruitment peri od may vary. The end 
of study will be defined as last subject last visit.  
6.3 Definitions 
Definition of treatment area : 
For this study , the term treatment area defines the body region in which the treatment field is 
located . The following treatment area s will be investigated:  
• Face : including forehead, excluding eyes, nostrils, and mouth  
• Scalp : bald scalp , excluding ears  
 
Definition of illumination area:  
The “illumination area” is the area effectively illuminated by one BF -RhodoLED® XL lamp  
in one illumin ation session. 
 
Definition of target lesions:  
Target lesions are all AK lesions (mild to severe) located within the treatment field  at Visit 1 . 
 
Definition of treatment field : 
The “treatment field” is the part  of the  skin to which IMP is applied.  
• The treatment field is defined as the skin surface area that is covered by IMP. In this 
study, the treatment field must comprise of a total skin area of approx. 60 cm² ( ~1 mm 
thick) and must contain at least 8 mild to moderate  AK lesions  with a diameter ≥4  
mm. In addition, severe A K lesions might be present. AK target l esions included in the 
study should be entirely located within the treatment field, leaving a  minimal distance 
of 1 cm of the lesion margin to the treatment field border. The treatment field has to be 
located on the face and/ or the scalp ( including forehead, excluding eyes, nostrils, ears, 
and mouth) . The treatment field may be continuous or in  several patches to form a 
total area of approximately 60 cm2. 
• In case of a discontinuous treatment field , all patches must  be located within one 
effective illumination  area. 
 
Definition of n ew lesions  
The term new lesion defines pre -neoplastic or neoplastic lesions in cluding  AK, NMSC such 
as BCC , SCC or Bowens disease, and melanoma that  occur inside or in close proximity (< 10 
cm distance) to the treatment field .  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 27 of 78   7 SELECTION OF S UBJECTS  
7.1 Number of subject s 
No sample size for the study was calculated. However, in agreement with FDA about 100 
subject s are considered sufficient to evaluate the safety profile after application of the content 
of 3 tubes of BF -200 ALA . All s ubjects will receive BF -200 ALA.   
7.2 Recruitment arrangements  
Subjects will be screened at the study site s and if eligible, included into the study  and 
subjected to PDT. Each site should dose  between 5 and 15 subjects . A study site has to stop 
recruitment once 20 subjects have been treated unless prior sponsor approval is obtained. The 
maximum number should not exceed 25 subjects.  Recruitment will be competitive within the 
limits described above . 
7.3 Inclusion criteria  
Eligible subjects must meet the following criteria:  
1. Willingness and ability of  subject s to provide informed consent and sign the Health 
Insurance Portability and Accountability Act (HIPAA) form. A study -specific 
informed consent and HIPAA form must be obtained in writing prior to starting any 
study procedures. 
2. Subjects with  mild to severe cl inically confirmed AK lesions (according to Olsen 
(Olsen et al., 1991) ) on the face and/or scalp. In case of severe AK lesions, a biopsy 
must be taken for confirmation of diagnosis. At  least 8 mild to moderate AK lesions  
with a diameter of   ≥4 mm must  be present in the treatment field.  The treatment field 
(continuous or in  several patches ) totaling about  60 cm2 must be located within one 
effective illumination area. The AK lesions should be clearly distinguishable, without 
restrictions on the distance between lesions. Lesions should have a  minimal distance 
of 1 cm between the lesion margin and the border of the treatment field. 
3. All sexes , ≥18 years of age . 
4. Willingness  and ability to comply with study procedures, particularly willingness to 
receive a PDT  session  and to undergo 2 mm punch biopsy /biopsies  in case of severe 
AK lesion (s) at the screening visit. 
5. Subjects with good general health or with clinically stable med ical conditions will be 
permitted to be included in the study. Subjects with clinically stable medical 
conditions will be permitted for inclu sion into the study if not using prohibited 
medication.   
6. Willingness to stop the use of moisturizers and any other non- medical topical 
treatments within the treatment field at least 24 h prior to the visits . 
7. Acceptance to abstain from extensive sunbathing and the use of a solarium  or tanning 
beds during the  stud y.  
8. For female subject s with reproductive potential: Negative serum pregnancy test.  
9. For female subject s with reproductive potential: Effective contraception at screening 
visit and t hroughout the study . 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 28 of 78   7.4 Exclusion criteria  
To reduce risks for the s ubjects  and to ensure that the subjects are in a comparable status, 
subjects will be excluded if they meet at least one of the following exclusion criteria:  
1. Any known history of hypersensitivity to ALA, porphyrins or excipients of BF -200 
ALA.  
2. History of soy or peanut allergy.  
3. Subjects with sunburn or other possible confounding skin conditions (e.g. wounds, 
irritations, bleeding or skin infections) inside  or in close proximity (<  10 cm distance) 
to the treatment field.  
4. Clinically significant (CS) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject’s safety such as: 
a. Presence of photodermatoses or porphyria  
b. Metastatic tumor or tumor with high probability of metastasis  
c. Infiltrating skin neop lasia (suspected or known)  
d. Unstable cardiovascular disease (New York Heart Association class III, IV)  
e. Unstable hematologic (including m yelodysplastic syndrome), hepatic, renal, 
neurologic, or endocrine condition  
f. Unstable collagen -vascular condition 
g. Unstab le gastrointestinal condition  
h. Immunosuppressive condition  
i. Presence of clinically significant inherited or acquired coagulation defect  
5. Clinical diagnosis of atopic dermatitis, Bowen’s disease,  basal cell carcinoma,  eczema, 
psoriasis, rosacea, squamous cell carcinoma, other malignant or  benign tumors inside  
or in close proximity (<  10 cm distance) to the treatment field.  
6. Presence of strong artificial pigmentation  (e.g. tattoos ) or any other abnormality that 
may impact lesion assessment or light penetration in  the treatment field.  
7. Any physical therapy such as cryo surgery , laser therapy, electrodessication, 
microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside or in close proximity (< 10 c m distance) to the 
treatment field within 4 weeks prior to screening.  
8. Any of the  topical treatments  defined below  within the designated periods  prior to 
screening:   
a. Topical treatment with ALA or ALA esters (e.g. methyl aminolevulinic acid (MAL)) or an investigational drug in-  and outside the treatment field  within 8 
weeks . 
b. Topical treatment with immunosuppressive , cytostatic or  cytotoxic drugs 
inside or in close proximity (< 10 cm distance) to the treatment field within 8 
weeks . 
c. Start of topical administration  of a medication with hypericin or other  drugs 
with phototoxic or photoallergic potential  inside or in close proximity (< 10 cm 
distance) to the treatment field within 4 weeks . Subjects may, however, be 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 29 of 78   eligible if such medication was applied  for more than 4 weeks prior to 
screening without evidence of an actual phototoxic/photoallergic reaction.  
9. Any use of the systemic  treatments  within the designated periods  prior to screening : 
a. Cytostatic or cytotoxic drugs within 6 months . 
b. Immunosuppressive therapies or use of ALA or ALA  esters (e.g. MAL) within 
12 weeks . 
c. Drugs known to have major organ toxicity within 8 weeks  or an investigational 
drug.  
d. Interferon or glucocorticosteroids within 6 weeks.  
e. Start of intake of medication with hyp ericin or systemically acting drugs with 
phototoxic or photoallergic potential within 8 weeks prior to screening. 
Subjects may, however, be  eligible if such medication was taken in for more 
than 8 weeks prior to t he screening visit without evidence of an a ctual 
phototoxic/photoallergic reaction.  
10. Breast feeding women.  
11. Suspicion of drug or alcohol abuse.  
12. Subject s unlikely to comply with protocol, e.g. inability to return for visits, unlikely to 
complete the study, or inappropriate in the opinion of the investigator.  
13. A member of study site staff or sponsor staff directly involved in the conduct of the protocol or a  close relative thereof.  
14. Simultaneous participation in another  clinical study . 
Re-screening  of subjects is allowed once in case exclusion criteri on 3 is  met and eligibility 
can be achieved within 14 days .  
 
Dosing day exclusion criteria:  
At Visit 2 (baseline, PDT -1) 
Subjects with sunburn or other possibl y confounding skin conditions (e.g. wounds, irritations, 
bleeding or skin infections) inside  or in close proximity (<  10 cm distance) to  the treatment 
field. Re -assessment of subjects is allowed within 14 days  once the sunburn or other 
confounding skin conditions is/are expected to resolve.  
7.5 Screening failures  
All subjects whose eligibility cannot be confirmed at Visit 1 and /or Visit 2 will be considered 
as screening failures . Re-assessment of subjects is allowed as described  in Section 7.4. 
Subjects assessed as screening failures will not be treated. Only date of i nformed c onsent, 
demogra phics and date and reason for screen fail have to  be reported  in the  eCRF .  
7.6 Subject s of reproductive potential  
Female subjects of reproductive potential (i.e. ovulating, pre -menopausal, or post -menopausal  
for less than one  year, not surgically sterile) must use a medically accepted contraceptive 
regimen during the study  as outlined below.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 30 of 78   • Use of one highly effective method proven to have an acceptably low failure rate 
(Pearl Index below 1, failure rate less than 1  % per yea r) such as : 
o surgical sterilization (e.g., bilateral tubal ligation, hysterectomy),  
o hormonal contraception (implantable, patch, oral , injectable)  
o sexual intercourse with a vasectomized partner  
o true abstinence  
• Combined use of two effective methods  such as : 
o latex condoms with spermicidal gel  
o Diaphragms with spermicidal gel  
o Cervical caps with spermicidal gel  
o Vaginal sponge with spermicidal gel  
 
Periodic abstinence (e.g. calendar, ovulation, symptothermal, post  ovulation methods) and 
withdrawal are not acceptable methods of contraception. If a subject becomes pregnant during the study , she must inform the investigator immediately.  
If pregnancy occurs, the investigator must contact the sponsor immediately for further 
instructions  and must be followed up until the outcome of the pregnancy is known. Both, the 
detection and the outcome of the pregnancy must be reported to the sponsor on special forms. Please also refer to S ection  12.1. 
 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 31 of 78   8 STUDY TREATMENT  
8.1 Details of investigational products  
 Investigational Medicinal Products  
The drug component of the investigational medicinal product (IMP)  will be BF -200 ALA, a 
gel formulation  of 7.8 % ALA . 
The compositions  are as follows:  
Table 2: Composition and manufacturer of study medication  
Drug  BF-200 ALA  
Brand name:  
Chemical name:  Ameluz®  
5-amino -4-oxopentanoat hydrochloride  
International non -proprietary 
name:  ALA hydrochloride  
Formulation:  BF-200 ALA containing 7.8  % ALA in a lecithin -based 
nanoemulsion gel with preservatives (sodium benzoate)  
and xanthan gum in purified water  
Manufacturer:  Biofrontera Pharma GmbH Hemmelrather Weg 201  
51377 Leverkusen, Germany   
ALA: 5 -aminolevulinic acid  
No excipients of human or animal origin are contained in the I MP or are used during the 
manufacturing process. Furthermore, no novel excipients are contained in the I MP used in this 
study.  
The BF -200 nanoemulsion gel is an oil -in-water dispersion of very small and homogenous 
vesicles, composed of a lipid core surrounded by a lecithin/co- surfactant monolayer. BF -200 
nanoemulsion has a mean vesicle size of less than 30 nm with a ve ry narrow size distribution. 
BF-200 ALA contains ingredients that are well established and approved worldwide in 
medicinal and cosmetic products. The formulation of BF -200 ALA, as applied in this study, is 
identical to the currently marketed formulation as  well as the formulation that was used in the 
confirmatory clinical trials summarized in  Section  4. 
The I MP will be delivered in aluminum tubes containing 2 g gel  (containing 156 mg ALA) . 
Three tubes will be provided per subject  for PDT , totaling in a total dose of 468 mg ALA  per 
PDT  an subject . The quantity of IMP provided for  PDT is sufficient to cover  the 60 cm2 skin 
area of the treatment field with a ~ 1 mm thick layer.   
 Investigational Medical Device  
The Class III device BF-RhodoLED® XL (in this document also referred to as investigational 
medical device, IMD)  allows the  illumination of a  larger area than the BF -RhodoLED® and is 
yet unapproved in the US .  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 32 of 78   BF-RhodoLED® was granted US marketing approval as a combination product with Ameluz® 
for the lesion-  or field -directed treatment of mild to moderate AK on the face and scalp in 
May 2016 (NDA 208081) . BF-RhodoLED® emits red light at a typical peak wave leng th of 
approximately 635 nm  and deliver s a total light dose  of 37 J /cm² within  10 min.  
The BF -RhodoLED® XL used in this study will be  manufactured  by a n ISO 13485:2016 
certified manufacturer : 
Biofrontera Pharma GmbH  
Hemmelrather Weg 201  
51377 Leverkusen 
Germany  
BF-RhodoLED® XL utilizes 225 LEDs ( 45 per panel arranged in a rectangle) to emit a 
uniform, visible red light with a typical peak wavelength at approximately 635 nm. The lamp 
is equipped with 5 LED panels  which will be positioned in a curved  shape. The maximal 
effective illumination area  in th is configuration is 23 cm x 29 cm ( 667 cm²) . 
The calibration of the lamp ensures that the skin area illuminated receives a total light dose of 37 J/cm
2 when maintaining a total illumination time of 10 min at a treatment distance between  
11 – 14 cm . Each LED panel is equipped with a distance sensor to enable individual 
adjustment of each  panel within this range. If a correct distance is achieved, it will be 
indicated a by a green light for each panel on the contr ol unit and the panel light s up with a 
low light intensity. The low light intensity will allow for correct adjustment of LED panels  
regarding distance and treatment field . The lamp is programmed to automatically provide a 
total illumination time of 10 min.  In case of necessary interruptions, e. g. due to pain or the 
need to reposition the subject , the lamp will continue until the required illumination time is 
achieved.  More details will be given  in the user manual BF -RhodoLED® XL. 
For the purpose of this study, each  study site will be equipped with one  BF-RhodoLED® XL. 
All site personnel handling the lamp will be instructed properly on the handling and usage of 
the lamp, according to the user manual.  
The recommended conditions for i llumination with the LED lamp are shown in Table 3.  
 
Table 3: Key light parameters of BF -RhodoLED® XL (curved shape)  
 Recommendation  
Peak wavelength ( ʎem) approx. 635  nm 
Light dose (energy)  approx. 37  J/cm²  
Typical i rradiance  61 (± 20 %) mW/cm2 
Typical i llumination time  10 min   
Typical d istance skin -lamp  12.5 cm (± 1.5 cm)  / 4.9 in (± 0.6 in) 
(range 11  - 14 cm / 4.3 - 5.5 in) 
 
Detailed handling and operating instructions as well as a list of warnings and precautions when handling BF -RhodoLED
® XL are provided in the user manual.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 33 of 78   In case of lamp failure the BF -RhodoLED® can be used. The BF -RhodoLED® is substantially 
equivalent to the BF -RhodoLED® XL in terms  of wavelength and light dose ( energy ). As in 
the BF -RhodoLED® XL the total light dose of 37 J/cm2 is achi eved in 10 min. Please note that 
in case the BF -RhodoLED has to be used, the distance to the t reated skin must range between 
5-8 cm. Please refer to the BF -RhodoLED® user manual  for details .   
8.2 Storage  
At the study site s, study medication  has to be stored at 2 °C to 8 °C (36 °F -46 °F) (rounded) in 
a temperature- controlled cabinet, located in an area inaccessible by unauthorized persons. 
Used study medication can be stored at room temperature . Temperature records (minimal-
actual -maximal or continuously records ) should be taken on a daily basis except for weekends 
and holidays  if manu ally recorded . Deviations (e.g. temperature measures outside the range of 
1.5 °C to 8.4 °C (35.5 °F -46.4 °F) or problems to store BF -200 ALA appropriately after 
delivery at study site) have to be immediately announced to the monitor and the sponsor, and 
study medication cannot be used unless sponsor’s release for this specific event was given.  
Transport of study medication  to the study site s will be temperature -controlled. The control of 
correct transport and measures to be taken in case of deviations are i n the responsibility of 
Biofrontera Pharma GmbH. Each delivered study medication cannot be used unless released 
by sponsor. 
The BF -RhodoLED® XL study lamp must  be stored  inaccessible to  unauthorized persons.  
8.3 Application of BF -200 ALA  
The treatment field  will be localized and documented as described in S ection  6.3 . A treatment 
field does not necessarily have to be continuous, but the (discontinuous) treatment field 
should cover a total area of approximately 60 cm2 and must allow illumination in one step 
(see S ection s 6.3 and 8.4 ). 
AK lesions located outside the specified treatment field will not be considered for treatment in 
this study . For treatment of these AK lesions , subjects will be treated according to standard of 
care at the discretion of the investigator  considering requirements in S ection  9. Most 
preferably, treatment of these lesions should be perform ed after final assessments at the end of 
the study  (Visit 5). The treatment field  should be prepared for IMP application by degreasing 
(using ethanol or isopropanol), removal of scabs and crusts, and if appropriate roughening of the surface, (e.g. by mild debr idement). Care should be taken to avoid bleeding , especially 
when screen ed subjects  report non- significant acquired or inherited coagulation defects and/or 
receive treatment with e.g.  81 mg acetylsalicylic acid per day or warfarin . 
After this preparation , the content of three tubes of the IMP will be administered  to the entire  
60 cm²  treatment  field , covering the skin with a film of approximately 1  mm thickness. A ll 
AK target lesions should have  a minimal distance of 1 cm to the border of the treatment field . 
The application will be performed  using glove -protected fingertips or a spatula . Care should 
be taken to avoid that the study medication is applied  to the upper and lower eyelids, the lip 
area (not past the vermilion border)  and in the nostrils . In case of accidental contact of study 
medication  with the eyes or mucous membrane s, rinsing with water for at least 5  min will be 
performed . 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 34 of 78   The IMP  will be allowed to dry for approximately 10  min, before a light -blocking , occlusive 
dressing (e.g. TegadermTM dressing plus aluminum foil) will be placed over the treatment 
field. After the incubation time of 3  h ± 10 m in, the light -blocking , occlusive dressing will be 
removed and the rem aining  gel shoul d be wiped off.  
 
 
The i ncubation time  starts  when light- blocking , occlusive dressing is placed and ends with 
removal of the IMP. Figure 2 illustrates the treatment procedure.  
 
 
 
 
 
Sequence of IMP application , placement of light -blocking, occlusi ve dressing , and illumination are specified . 
After dr ying of the applied study medication , incubation time  starts with placement of the light -blocking 
dressing  and ends with the removal of remaining gel followed by red light illumin ation.  
Figure 2 : Sequence  of BF -200 ALA  application, placement of light -blocking, occlusi ve 
dressing , and illumination at Visit 2.  
 
The fo llowing information  concerning  this procedure will be documented in the  eCRF : 
• Preparation of the treatment field including lesions  
• Occurrence of bleedings in the application area  
• BF-200 ALA application start time  
• Incubation time: start and stop time  
 
8.4 Illumination with BF-RhodoLED® XL 
After removal of remaining gel, the entire treatment field will be illuminated for 10 min with  
the BF-RhodoLED® XL until a total light dose of approximately 37  J/cm2 is achieved. During 
illumination, the lamp will be positioned in 11 cm to 14 cm (optimum: 12.5 cm) distance from 
the skin surface as indicated in the user manual. Please also refer to S ection  8.1.2. 
In case of  a discontinuous treatment field  the treatment field must be covered by one 
illumination area.  
During illumination, subjects and medical personnel must wear suitable protective eye 
goggles, even if PDT is performed in areas where little light reaches the subject’s eyes.   
Detailed handling and operating instructions as well as a list of warnings and precautions when handling BF -RhodoLED
® XL can be derived from the user manual.  
3 h ± 10 min  
treatment  
procedures  
incubation  
removal of  
dressing & gel  
illumination  
 
light blocking  
dressing  
Application of  
BF-200 ALA  
drying of gel  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 35 of 78   Discomfort and pain during illu mination  are caused by the intended phototoxic reaction. 
Although the emitted  light is in the visible red spectrum and has no emission in the (heat -
transmitting)  infra -red light  spectrum , submitted energy to the skin may create a warming 
sensation. In addi tion, some subjects may have the feeling of being burned. The latter is 
caused by a transient physiological reaction, which is  in some subjects very unpleasant . The 
underlying  biochemical reaction during illumination  involves the activation of heat sensiti ve 
nerve endings in the skin, which may be enhanced by a strong psychological component  (31). 
As pain might be experienced during illumination  investigators may consider to apply pain 
relieving measures  prior to, during or post  illumination considering requirements outlined in 
Section  9.2. However, pain will be evaluated by all subjects after the treatment . 
The subject should be informed about restrictions  defined in Table 4 and in Section  9.2. 
Although a nearly complete loss of PpIX by photobleaching is assumed to occur during 
illumination , subjects should avoid exposure to intensive sun light for about 48 h since new 
PpIX may  accumulate from remaining ALA. Thus, a dditional light exposure  may enhance the 
typical side  effects of PDT. Subjects should not expose themselves to intensive ultraviolet 
(UV) -radiation (solarium, sun bathing, etc.) during the course of the study (see also Section  
7.4) to avoid UV  induced post inflammatory hyperpigmentation of the healing tissue.  
A surgical dressing of the treated area is normally not required  and should be avoided 
whenever possible. 
 The following information c oncerning this procedure will be documented in the eCRF:  
• The correct distance within the indicated range was achieved prior to the start of 
illumination (yes/no)  
• Panel number of used panels  
• Illumination time : start and stop time  
• In case of premature termination: reason for premature termination, remaining 
treatment time and applied light dose  
• In case of interruption(s): frequency of interruption(s), total duration of interruption(s), reason for interruption(s)  
• Pain intensity repor ted by the subject during illumination (according to NRS -11) 
• Pain relieving measures taken  prior to, during and post  illumination  (physical 
measures (e.g. cold compress, cooling, nebulized water) and/or  concomitant 
medication ) 
8.5 Dosage schedule  
One PDT session  with the content of 3 tubes of BF-200 ALA  will be applied according to the 
study design described in S ection  6.1, S ection 8.3, Section  8.4 and Figure  1. 
8.6 Treatment  assignment  
This is a non- randomized, open- label study, i.e., all eligible subjects will receive active 
treatment.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 36 of 78   8.7 Blinding, packaging, and labeling  
This is an open- label study. i.e., blinding is not applicable..  
 Investigational medicinal product  
The sponsor will ascertain that all study medication  is manufactured and packaged in 
accordance with regulatory requirements and the principles of Good Manufacturing Practice 
(GMP).  
Responsible for manufacturing and release of  BF-200 AL A: 
Biofrontera Pharma GmbH  
Hemmelrather Weg 201  
51377 Leverkusen 
Germany  
The appropriate number of tubes and cardboard boxes will be labeled in English according to the pre -defined distribution of identification numbers. The labels will include all information 
required by 21 CFR 312.6 (including the statement: “Caution: New Dr ug—Limited by  
Federal  (or United States ) law to investigational use”).  
For each subject, a card board  box is provided containing three  tubes with BF -200 ALA . Each 
box is labeled with tear -off label and can be identified and assigned to a specific subject by a 
unique identification  number.  
In addition, each tube will be labeled accordingly. This label information must be documented 
in the appropriate space in the subject’s source data when the I MP is dispensed prior to PDT. 
Additional statements may be printed on the label as required by local regulations.  
The sponsor will maintain a complete record of batch numbers and expiry dates of  the IMP 
and the labels of the I MP in the Trial Master File  (TMF) . 
 Investigational medical device  
BF-RhodoLED® XL will be distributed , installed  and maintained at the sites by technicians  or 
other properly trained delegates  of: 
Biofrontera Inc.  
120 Presidential Way , Suite 330 
Woburn, MA 01801  
USA 
The appropriate number of lamps will be labeled in English as investigational device in 
accordance with 21 CFR 801.1 and 21 CFR 812.5. Labels will include:  
• the name and place of business of the sponsor, manufacturer, and distributor  
• the statement: “CAUTION Investigational device . Limited by Federal (or United 
States) law to investigational use”).  
• and/or references to all relevant contraindications, hazards, adverse effects, interfering 
substances, warnings and precautions.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 37 of 78   For the purpose of this study, the s tudy sites  will be pr ovided with one  BF-RhodoLED® XL 
lamp.  It is exclusively intended to be used in conjunction with study medication within the 
scope of clinical trials conducted by Biofrontera . As the lamp will be installed  at the  site by a 
technician  or delegate of Biofront era, there will be no immediate packaging available. All 
labeling  will be applied directly to the lamp.  
8.8 Supplies and accountability  
After the study protocol is  approved or accepted by the Institutional Review Board(s) (IRB(s)) 
and by FDA, the sponsor will initiate the study site s which includes installation  of a BF-
RhodoLED® XL lamp, and thereafter supply the  study site s with study medication , together 
with all relevant documentation. The sponsor is responsible for delivery  of the investigational 
products  to the study site s. 
The investigator will inventory and acknowledge receipt of all shipments of the IMP and 
IMD . The investigator is responsible for maintaining  documentation showing the amount of 
investigational products  provided to the study site  and the used  IMP for each study subject. 
Discrepancies in accountability  of the investigational products  must be explained and 
documented. The monitor is responsible to  verify the investigator’s documentation on receipt, 
use, and return of the investigational products . The monitor will check drug and medical 
device accountability at the study site s on an ongoing basis during the study. At the end of the 
study, all remaining study medication or empty tubes must be returned to the drug supplier 
acting on behalf of Biofrontera Pharma GmbH for disposal. The monitor will prepare a final 
report of accountability  of the investigational products  for filing in the investigator s ite file 
(ISF).  
After the last subject completed the treatment  and no further trial s are planned, all lamps will 
be returned to Biofrontera Inc. Receipt and return of BF -RhodoLED® XL will be 
acknowledged and documented accordingly.  
8.9 Compliance  
The application of study medication will be administered/supervised by the investigator or 
subinvestigator. Any delegation of this responsibility should follow the guidelines stated in 
Section  15.2. 
The study medication will n ever be handed out to the subjects, rendering individual 
compliance assessments unnecessary.  
BF-RhodoLED® XL lamp will be exclusively operated by previously trained study personnel.   
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 38 of 78   9 PRIOR AND CON COMITANT MEDICAL CONDITIONS  AND 
TREATMENTS 
9.1 Prior and concomitant medical condition s 
Medical history is an account of medical events that the subject has experienced in the past.  
The medical history will be recorded in the source data. However, only relevant  medical 
history as judged by the investigator will be recorded in the eCRF. The investigator must 
document in the source data, which medical history is considered relevant for this study. For 
this study, transient amnestic episodes and TGA are considered releva nt (28). 
Diseases or illnesses including skin conditions present at the time of signing the informed consent are regarded as concomitant medical conditions  and will be recorded in the eCRF.   
Medical  conditions  first occurring or detected during the study, and worsening of a 
concomitant condition during the study, are to be regarded as AEs and must be documented in the AE section of the eCRF (see S ection  11). 
 Medical s kin history  
At the screening visit relevant medical skin history  as judged by the investigator  should be 
documented in the  eCRF . In case of AK, NMSC and melanoma history the  followi ng 
information will be documented in the eCRF  additionally : 
• Is this the first diagnosis of AK? If AK w as diagnosed in the past, indicate date of f irst 
AK diagnosis .  
• Were AK lesions diagnosed in the past located within the selected treatment area (s)? If 
previous AK events were treated in this treatment area(s), please indicate therapy  and 
start date of therapy .  
• Were there diagnoses of NMSC ( e.g. BCC, SCC, Bowens disease) or melanoma in the 
past? If yes, report  indication and first diagnosis and the total number  of diagnosed 
lesions (1, 2- 5, > 5) since first diagnosis . In case, such a lesion was diagnosed in the 
past, did the lesion occur within the  selected  treatment area (s)?  
For other relevant skin history th e information about indication  and date of fi rst diagnosis is 
sufficient.  
9.2 Prior and  concomitant medication s/treatments  
Any medication taken by a  subject  or treatments  the subject is undergoing that are not related 
to any study -specific procedures (PDT with IMP) , startin g with  the time of signing the 
informed consent until the end- of-study  are considered  concomitant medic ations or 
treatments. The use of required concomitant  medications or  treatments, which are known not 
to interfere with the I MP or to mask its  effect, is unrestr icted and may be continued during the 
study.  
The following treatment s are examples for  permitted treatments in the designated time  periods  
to alleviate pain and discomfort  (please consider the information provided in the respective 
PIs). Other treatments are also allowed as long as they are not explicitly forbidden in Table 4:  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 39 of 78   • Prior to illumination  
o Acetaminophen (e.g. Tylenol®), ibuprofen up to 1200 mg per day , aspirin up to 
3750 mg per day , ice gel/spray and/or  application or inject ion of  a local, fast -
acting anesthetic, such as xylocaine or lidocaine . 
• During illumination  
o In cases where the pain is regarded as unbearable by the s ubject, the 
illumination  may be interrupted and/or cooling with an air stream and/ or 
nebulized water may be offered.  
o Severe cases of pain  might require to briefly  interrupt illumination, e.g. to 
inject  or apply  a local, fast -acting anesthetic, such as xylocaine or lidocaine  or 
to cool briefly with cooling packages . 
• Treatment of pain and discomfort post  illumination  
o Cooling the illuminated area(s) with wet or refrigerated  compresses  
o Analgesic treatment with acetaminophen (e.g. Tylenol®) or NSAIDs 
(ibuprofen up to 1200 mg per day / aspirin up to 3750 m g per day ) 
o Application of an analgesic cream  
All concomitant medications/treatments  or relevant concomitant medications/treatments  
taken /underwent  during the study , must be documented i n the eCRF along with the indication, 
route of administration , single  dose , frequency of administration, as well as start and stop date 
of administration. The subject should confer with the investigator prior to the use of new  
medication  until the end of the study . 
The following concomitant treatments/procedures are not permitted : 
• Any therapy such as cryo surgery , laser therapy, electrodessication, surgical removal of 
lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside 
or in close proximity (< 10 cm distance) to the treatment field 4 weeks prior to screening until end- of-study . Lesions may be treated with these methods if the 
distance to the treat ment  field is more than 10 cm.  
• A list of forbidden, concomitant medication is provided in  Table 4.  
If the in vestigator, at any time in the study, suspects a lesion inside  or outside the treatment 
field to have progressed into a manifest malignancy, they should refer the subject for standard medical treatment, irrespective of whether or not this results  in exclusion of the subject from 
the study .  
Table 4: List of forbidden concomit ant medication  with designated time period s. 
Medication  Topical administration  Systemic administration  
 start of 
restriction   forbidden until start of  
restriction   forbidden  
until 
ALA  or ALA -esters 
(except I MP at Visit 
2) 8 weeks   
prior to Visit 1  end-of-study  12 weeks   
prior to Visit 1  end-of-study  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 40 of 78   Medication  Topical administration  Systemic administration  
 start of 
restriction   forbidden until start of  
restriction   forbidden  
until 
Cytotoxic drugs / 
Cytostatic drugs  8 weeks  
prior to Visit 1 
inside or in close proximity (< 10 cm 
distance) to  the 
treatment field  end-of-study  
inside or in close proximity (< 10 cm 
distance) to the treatment field  6 months  
prior to Visit 1  end-of-study  
Immuno suppressive 
therapies  8 weeks  
prior to Visit 1 inside or in close proximity (< 10 cm 
distan ce) to  the 
treatment field  end-of-study  
inside or in close proximity (< 10 cm 
distance) to the treatment field  12 weeks  
prior to Visit 1  end-of-study 
7 days  
prior to PDT  
inside and outside  the 
treatment field  7 days  
post PDT 
inside and outside  the 
treatment field  
Interferon  --- --- 6 weeks  
prior to Visit 1  end-of-study  
Glucocorticosteroids  (allowed)  (allowed)  6 weeks  
prior to Visit 
1a end-of-studya 
NSAIDs  (others 
than listed below)  7 days  
prior to PDT  7 days  
post PDT  7 days  
prior to PDT  7 days  
post PDT  
Acetylsalicylic acid  
> 3750 mg/day  --- --- 7 days  
prior to PDT  7 days  
post PDT  
Ibuprofen 
> 1200 mg/day  --- --- 7 days  
prior to PDT  7 days  
post PDT  
Diclofenac  7 days  
prior to PDT within illumination area(s)
b 7 days  
post to PDT within illumination area(s)
b > 100 mg/day;  
7 days  
prior to PDT  > 100 mg/day;  
7 days  
post PDT  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 41 of 78   Medication  Topical administration  Systemic administration  
 start of 
restriction   forbidden until start of  
restriction   forbidden  
until 
Hypericin or drugs 
with phototoxic/  
photoallergic 
potentialc 4 weeks  
prior to Visit 1  
inside or in close proximity (< 10 cm distance) to the 
treatment field  end-of-study  
inside or in close proximity (< 10 cm distance) to  the 
treatment field  8 weeks  
prior to Visit 1  end-of-study  
Investigational 
drugs  8 weeks  
prior to Visit 1  end-of-study  8 weeks  
prior to Visit 1  end-of-study  
Drugs known to 
have major organ toxicity  --- --- 8 weeks  
prior to Visit 1  end-of-study  
Medication that 
influence coagulation 
(e.g. 
anticoagulants, anti -
platelet drugs)  --- --- Visit 1  
(may be used 
throughout the 
study if taken in a 
stable dose prior 
to study)  end-of-study 
(may be used 
throughout the 
study if taken in a 
stable dose prior 
to study)  
EMLA® cream  On day of PDT  
inside or in 
close proximity (< 10 cm 
distance) to the 
treatment field  On day of PDT  
inside or in close proximity (< 10 cm 
distance) to the 
treatment field  --- --- 
a Not for inhaled  glucocorticosteroids . 
b Topical use of diclofenac up to 2.5 % may be used outside illumination area(s) throughout the study.  
c Start of therapy with any photosensitizer or systemically -acting drugs with phototoxic or photoallergic 
potential, such as psoralenes, tetracyclines, nalidixic acid, furosemide, amiodarone, phenothiacines, chinolones, 
fibrates, or phytotherapy with St. Joh n’s wort, arnica, or valerian or topically applied phototoxic substances like 
tar, pitch, psoralenes or some dyes like thiazide, methylene blue, toluidine blue, eosin, rose b engal, or acridine 
within  4 weeks for topical administration or  8 weeks  for system ic administration  prior to screening. Subjects  
may, however, be eligible if such medication was taken  longer than 4  weeks (topical) or  8 weeks  (systemic)  prior 
to screening without evidence of an actual phototoxic/photoallergic reaction.   
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 42 of 78   10 STUDY PROCEDURES AND SCHEDULE  
All data obtained  from su bjects, e.g. assessments, questionnaires and examination results , 
should be sufficiently documented in source.  
10.1 Description of study days  
Table 1 summarizes the study schedule.  
 Screening  visit ( ≤ 14 days prior to PDT)  
Potential subjec ts will be evaluated to determine if they fulfill the inclusion and exclusion 
criteria (see S ection s 7.3 and 7.4).  
Each subject will be assigned a s ix-digit subject number (consisting of a three- digit site 
number and a three -digit subject screening number) in the chronological order of enrollment 
within each site (e.g. 801 -001). For this purpose, the next higher subject number is always 
assigned. This number will be documented and will be used to identify the subject. New 
subjects must always be assigned a new subject number.  
The following procedures will be performed at Visit  1 (screening ) and recorded in the eCRF : 
• Obtain informed consent prior to any s tudy-related procedures  
• Assign subject number  
• Obtain demographic data  
• Document concomitant medical conditions and  relevant medical history  
• Document  medical skin history (including NMSC  (such as BCC , SCC or Bowens 
disease) , melanoma , AK and other skin diseases)  
• Document concomitant medication s/treatments  
• Document body measures  
• Measure vital signs  
• Physical examination   
• Neurological assessments  
• Check inclusion and exclusion criteria  
• Assess skin type according to Fitzpatrick, 1988 ( 32) 
• Select  the treatment field and assess AK target  lesions (size, number, location and 
clinical severity assessment according to  Olsen  et al. , 1991 ( 33)). In case of severe AK 
lesions, a biopsy must be taken for confirmation of diagnos is. 
• Generat e graphic template s of the treatment field and location of AK target lesions on 
provided cartoon. T he location of the  treatment field and the AK lesions within in the 
treatment field as well as any AK lesions in close proximity (<  10 cm distance) to the 
treatment field should marked on a grid foil for re -identification during the course of 
the study.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 43 of 78   • Clinical laboratory tests (including routine hematology  and blood chemistry , serum 
pregnancy test  for females of reproductive potent ial, and urinalysis) . Please document 
if the subject was in a fasted state or not.  
• Documentation of (S)AEs . 
• Instruct subject  about forbidden concomitant medication s/treatments (see S ection  9.2 
and Table 4) . 
 Visit 2/ Baseline/ Treatment  (PDT)  
The following procedures will be performed at Visit  2 and recorded in the  eCRF : 
• Re-evaluation of inclusion and exclusion criteria  for confirmation of subje ct’s 
eligibility  
• Evaluation of dosing day exclusion criterion  
• Neurological assessments  prior to PDT and 60 (±10) min after end of illumination 
• Skin assessment regarding new lesions (AK, NMSC, and melanoma) inside or in close 
proximity (< 10 cm distance) to the  treatment field . NOTE: Occurrence of NMSC and 
melanoma  will lead to exclusion of the subject  
• Pregnancy test (urine)  for females of reproductive potential  prior to PDT  
• Measurement of vital signs after subject’s arrival  at the site, within 10 min before  start 
of illumination, within 10 min after end of illumination and 60 ( ±10) min after end of 
illumination  
• Preparation of the treatment field  and a dministration  of study  medication  (3 tubes ) 
should be applied to a total ar ea of approx. 60 cm²) , and after  drying of the gel 
application of a  light -blocking , occlusive dressing according to treatment  description 
in Section  8.3 
• Illumination of  the treatment field with the BF -RhodoLED® XL lamp  until a total light 
dose of 37 J/cm² is achieved ( according to treatment description in S ection  8.4). In 
case of a discontinuous treatment field  all patches  must be within one illumination  
area (see S ection  8.1.2)  
• Assessment of application site pain d uring illumination  via NRS -11 
• Documentation of (S)AEs including application site skin reactions, application site discomfort , and  new lesions . Application site skin reactions and application site 
discomfort should be assessed directly after illumination  (within 10 min)  and should 
be re- assessed 60 (±10)  min after end of illumination  (occurrence and severity).  
• Documentation of concomitant medications/treatments including medications/treatments for pain management that might be required prior to, during or  
post illumination  (see Section  9.2 and Table 4)  
• Inform  subjects to avoid sunlight, prolonged or intense light (e.g., tanning beds, sun 
lamps) on the  treatment field for approximately 48 hours following treatment whether 
exposed to illumina tion or not  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 44 of 78   • Explanation and handout of subject diary  to document AEs , their impact on the 
subject’s daily life, and concomita nt medication until the end of the study  
 Visit 3 Safety Interim Visit (7 (± 2) days post PDT)  
The following procedures will be performed at Visit 3 and recorded in the eCRF:  
• Measurement of vital signs  
• Skin assessment regarding new lesions (AK, NMSC, and melanoma ) inside or in close 
proximity (< 10 cm distance) to the  treatment field since the last visit 
• Documentation of concomitant medications/treatments (please see also listing of 
allowed and restricted medications in Section  9.2) with consideration of subject ’s 
diary  
• Documentation of (S)AEs, including application site skin reactions and application 
site discomfort, and new lesions  with consideration of subject’s diary  
 Visit 4 Safety Interim Visit (14 (± 2) days post PDT)  
The following procedures will be performed at Visit 4 and recorded in the eCRF:  
• Measurement of vital signs  
• Skin assessment regarding new  lesions (AK, NMSC, and melanoma) inside or in close 
proximity (< 10 cm distance) to the treatment field since the last visit 
• Documentation of concomitant medications/treatments (please see also listing of 
allowed and restricted medications in Section 9.2)  with consideration of subject’s 
diary 
• Documentation of (S)AEs, including application site skin reactions and application site discomfort, and new lesions  with consideration of subject’s diary  
 Visit 5 Final Visit (28 (± 7) day post PDT)  
The following procedures will be performed at Visit 5 a nd recorded in the eCRF:  
• Measurement of vital signs  
• Physical examination  
• Collection of blood and urine samples for safety laboratory tests including serum 
pregnancy test for females with reproductive potential and urinalysis  
• Skin assessment regarding new lesions (AK, NMSC, and melanoma) inside or in close 
proximity (< 10 cm distance) to the treatment field since the last visit 
• Documentation of concomitant medications/treatments (please see also listing of allowed and restricted medications in Section  9.2) with consideration of subject’s 
diary  
• Documentation of (S)AEs, including application site skin reactions and application 
site discomfort, and new lesions  with consideration of subject’s diary  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 45 of 78   • Collection of subject diary 
 Unscheduled visit  
In case of unexpected safety assessments  unscheduled visits can be performed. 
10.2 Assessments  
 Evaluation of demographic data  
The following information will be obtained as demographic data  from all participants  at 
screening visit : 
• Sex 
• Age 
• Race  
• Ethnicity  
 Body measures  
The following information will be obtained as body measures from all participants at 
screening visit : 
• Height  (in) 
• Weight  (lb) 
 Clinical criteria for diagnosis of AK  
Lesions will be considered AK if they present clinically as rough, crusted, flesh- colored to 
reddish- brown papules, or with an adherent scale in a field of sun- damaged skin  (34–36) . 
AK lesion severity will be ev aluated according to the Olsen Severity Grading  (33) as follows:  
• No AK/ grade 0  i.e. no AK lesion present, neither visible nor palpable  
• Mild/grade 1 AK lesions  should present flat, pink maculae without signs of 
hyperkeratosis and erythema. The  lesions should be slightly palpable, with AK better 
felt than seen.  
• Moderate/ grade 2 AK lesions  should present as pink to reddish papules and 
erythematous plaques with hyperkeratotic surface. These AK lesions should be 
moderately thick and can be easily seen and felt.  
• Severe/ grade 3 AK lesions  should present as very thick plaques with hyperkeratotic 
surface. These AK lesions should be very thick and/or obvious. 
Additionally, a  biops y must be obtained for every  severe AK lesion  to confirm the diagnosis 
of AK  at the screening visit . 
Clinical Study 
Protocol
 
 
2
1
-
Apr
-
202
2
 
ALA
-
AK
-
CT01
8
 
 
 
Amended 
Version 
3
.0
 
 
 
Biofrontera Bioscience GmbH 
–
 
Confidential
 
 
page 
46
 
of 
78
 
 
 
Assessment of 
AK 
target lesions
 
and documentation of new lesions
 
In this
 
clinical trial,
 
at least 
8 
AK lesions
 
of 
mild to 
mod
erate
 
intensity (according to
 
Olsen
 
et 
al.
, 1991
) 
with a minimal dia
meter of 
4
 
mm 
must
 
be pre
sent in the treatment field. All lesions 
located
 
within the treatment field
 
including 
AK lesions <4 
mm 
as well
 
as severe AK lesions
,
 
will be treated with
 
field
-
directe
d
 
PDT.
 
Lesions included in the study should be 
distinguishable and entirely located within the treatment field, with a minimal distance of 1 
cm between the lesion margin and the border of the treatme
nt field. However, no distance 
restrictions between lesions will be applied. 
 
All 
AK 
target 
l
esions within the treatment field have to be counted
 
and 
location (treatment 
area) ha
s
 
to be documented 
at 
V
isit 1
.
 
In addition, 
the severity 
of the 
AK 
target 
lesions
 
≥
4 
m
m
 
and 
the
ir
 
size 
should be recorded by measuring the diameters (for non
-
circular lesions, the 
largest diameter and the corresponding perpendicular diameter will be measured)
. 
AK target 
lesions 
≥4 mm
 
should also be numbered. 
AK target lesions <
4 
m
m 
should only be counted. 
T
otal lesion area
 
of
 
all
 
lesions 
≥4 
m
m
 
in the treatment field 
will be 
automatically 
calculated
 
in 
the eCRF
.
 
The treatment field 
and the location of AK target lesions 
should be clearly sketched in the
 
provided
 
cartoon
. 
The locat
ion of 
the
 
treatment field and 
the 
AK target lesions in the 
treatment field 
should
 
also 
be 
marked on a grid foil.
 
Furthermore, at Visit 1 
any AK lesions in 
close proximity (< 10 cm distance) to
 
the
 
treatment field 
must be 
plotted
 
on a grid foil
, if 
applicable,
 
for identification of new 
AK 
lesions
 
during the course of the study.
 
At Visit 2 new 
AK lesions
 
inside or in close proximity (< 10 cm distance) to 
the 
treatment field
 
must be 
documented on the grid foil
, if applicable
.
 
These n
ew AK lesions must 
be documented as A
Es 
and
 
will be treated, if located within the treatment field, but will not be considered as AK 
target lesions.
 
NOTE: Occurrence of 
NMSC and melanoma
 
will lead to exclusion of the 
subject. 
At 
further visits
 
all 
new lesions (AK, NMSC, and 
melanoma) inside or in close 
proximity (< 10 cm distance) to
 
the
 
treatment field 
must be 
drawn
 
i
n the grid foil
 
and 
documented as AEs
.
 
 
Biopsy
 
A 2 mm punch biopsy will be taken from every severe AK lesion at the screening visit to 
confirm the diagnosis of A
K.
 
The biopsies will be histopathologically evaluated by a central 
dermatopathological laboratory.
 
Containers with fixation solution and shipping material will be provided by the central 
laboratory to the study centers.
 
The following laboratory is responsi
ble for evaluating the biopsies
:
 
 
 
 
 
Assessment of skin type
 
Subject
s’ skin type will be assessed at 
the 
screening 
visit using the six
-
level 
Fitzpatrick
 
Skin 
Type Rating Scale
 
(
32
)
. F
urt
her details are provided in 
Appendix 
19
A
.
 

Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 47 of 78   
 Safety  
Safety measurements will be performed at the time points given in the study schedule  (see 
Table 1).   
 
Physical examination  
The physical examination will involve  head , neck, skin, lymph nodes, thorax including heart 
and lungs, abdomen, and musculoskeletal, peripher al vascular and nervous system status.  
The outcome of the physical examination should be documented for each of these body 
systems. In the eCRF, only abnormal findings that are considered clinically significant are 
required to be reported. Clinically significant  findings  will be documented in the medical 
history (Visit 1) or afterwards as AEs.  
 
Neurological Assessments  
The following assessments serve mainly as an orientation to exclude gross neurological 
defects, e.g. a potential amnestic episode. Abnormal findings that are considered clinically 
significant will be documented in the medical history (Visit 1) or afterwards as AEs.  
 
I Memory test – Part A  
Three different picture sets (set A, set B and set C) will be provided. For each 
assessment timepoint a different set should be used. The subject should be presented 
with 3 different pictures from a specific set before the neurological investigation, 
which they should memorize. 
II Neurological investigations  
Investigation of the pupils (equality), coordinati on (finger -nose test), gait (balance), 
and sensitivity (cheeks, arms, legs).  
III Memory test  – Part B  
The following questions will be asked to the subject:  
- Can you tell me your date of birth, first and last name?  
- What day of the week is it today ? 
- When did you arrive at the site today ? 
- Why are you here?  
- Do you remember the PDT? (only at Visit 2 after PDT)  
After the neurological investigations and answering the questions, all 5 pictures of the set will be presented to the subject who will be asked to identif y the 3 pictures 
presented at the beginning of the examination. 
 
Vital signs  
Clinical Study 
Protocol
 
 
2
1
-
Apr
-
202
2
 
ALA
-
AK
-
CT01
8
 
 
 
Amended 
Version 
3
.0
 
 
 
Biofrontera Bioscience GmbH 
–
 
Confidential
 
 
page 
48
 
of 
78
 
 
Blood pressure (systolic and diastolic) and pulse rate will be measured after 
5
 
min rest in 
supine position
. 
Measurement of body temperature (
°
F
)
.
 
 
Safety laboratory
 
Blood and urine sampling for clinical safety analysis 
can
 
be performed in a 
non
fasted state. 
However, 
fasting
 
state must be documented
 
in source data
. 
Fasting is defined as abstinence 
fr
o
m food and beverage consumption (other than water) for at least 
8
 
hou
rs.
 
The following central laboratory is responsible for 
blood 
safety laboratory assessments:
 
 
 
 
•
 
Blood
 
An 
approximately
 
3
 
ml
 
EDTA (ethylenediaminetetraacetic acid)
 
blood sample, 
and a
n 
approximately
 
7
.
5
 
ml
 
serum sample 
will be collected
. 
The total blood loss for safety 
laboratory examinations will be approximately 
21
 
ml
.
 
-
 
Clinical chemistry parameters
 
G
lucose, creatinine, total bilirubin, aspartate aminotransferase (AST), alanine 
aminotransferase 
(ALT), lactate dehydrogenase (LDH), alkaline phosphatase (AP), 
gamma glutamyl transferase (GGT), potassium, sodium, calcium, total protein, 
albumin
 
-
 
Hematology parameters
 
Hemoglobin, hematocrit, red blood cell count, leukocyte count (white blood cells 
(WBC)
) with differential count (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils), and platelet count.
 
•
 
Urine
 
A
n
 
approximately 
30
 
m
l
 
urine sample
 
will be collected 
.
T
he following parameters will be 
measured
:
 
-
 
Urinalysis parameters
 
Glucose, bilirubin, 
ketone
s
, specific gravity, blood
, pH, protein, 
urobilinogen, nitrite, 
leucocytes
.
 
Urinalysis will be performed at the investigational site from a sample of fresh mid
-
stream 
urine using a dipstick.
 
 
Pregnancy test in females 
of 
reproductive 
potential 
 
A ser
um pregnancy test (
β
-
h
uman chorionic gonadotropin
 
(
β
-
hCG
)
 
test) 
will be performed at 
screening (
Visit
 
1
)
 
and 
28 days
 
after the PDT (
Visit 
5
)
.
 
A
t
 
PDT
-
visit
 
(
Visit 
2
),
 
a 
urine dip
-
stick pregnancy test
 
will be performed
.
 
 

Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 49 of 78   Adverse events  
During the study , all (S)AEs have to be recorded as outlined in Section  11. If possible, each 
subject should be assessed by the same investigator/staff personnel thr oughout the study.  
• Application site reactions  
The term application site reaction encompasses all reactions occur ring in the treatment field 
after starting PDT treatment and can be subclassified into the more specific categories 
application site discomfort and application site skin reactions.  
 
• Application site discomfort  
At Visit 2, application site discomfort during and after PDT, and at Visit 3 to Visit 5 
application site discomfort after PDT will be assessed asking non -leading questions 
like “Have you noticed anything in the treatment surrounding areas since we last saw you?” Any signs or symptoms reported by the subject that correspond to the 
application site discomfort categories as outlined below should be assessed as 
described in Section  11.1.1.  
Application site  discomfort categories are for example:   
• Burning 
• Hyperaesthesia  
• Pain 
• Paraesthesia  
• Pruritus  
• Stinging  
• Warmth  
• Other  
 
• Application site skin reactions  
Application site  skin reactions will be evaluated  by the investigator (or delegate)  during 
and after PDT at Visit 2 and at Visit 3  to Visit 5 . The AE severity  grading should be 
used (see S ection  11.1.1) .  
The application site  skin reaction  categories listed below will be checked by visual 
inspection of the respective subject ’s treatment field (and documented on (S)AE eCRF 
page).   
Application  site skin reaction categories are for example:   
• Discharge  
• Erosion 
• Erythema  
• Exfoliation  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 50 of 78   • Fissure  
• Induration  
• Oedema  
• Scabbing 
• Skin flaking 
• Ulceration  
• Vesicles  
• Other  
 
• Assessment of pain at the application site during illumination  
At Visit 2, subjects will assess the pain experienced during  illumination using an 11 -
point Numeric Rating Scale (NRS -11) ranging from 0 (no pain at all) to 10 (worst 
possible pain). This score should reflect the subject’s respective maximum pain during 
illumination .  
Pain during illumination is not documented as separate AE, as it is considered as resulting from the intensity of other modalities, e.g. burning, stinging. These modalities 
(i.e. burning, stinging, itching) are documented and pain is rated via  NRS -11. However, 
documenting pain as individual, additional AE is considered a double documentation. If pain is not related to illumination (e.g. neuropathic pain, headache) this is to be 
documented as AE nevertheless.  
• New lesions  
Any new lesions (AK, NMSC such as BCC, SCC or Bowens disease , and melanoma ) inside 
or in close proximity (< 10 cm distance) to the treatment field ha ve to be reported (see Section 
10.2.4) . 
 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 51 of 78   11 ADVERSE EVENTS  
11.1 Definitions 
 Adverse events  
Adverse event means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. This includes any unfavorable and 
unintended sign, symptom, syndrome, or illness that develops or worsens during the cl inical  
study whether or not related to the investigational products and the study procedures.  
For the purpose of the study, c linically significant  abnormal results of diagnostic procedures 
including abnormal laboratory findings (e.g. requiring unscheduled diagnostic procedures or treatment measures or resulting in withdrawal from the study) discovered at screening will be 
related to medical history or are considered to be AEs  if they are detected post screening . Any 
AEs first occurred or worsened in severity post treatment are considered as treatment -
emergent adverse event (TEAE) .  
The severity  of AEs should be assigned to one of the following catego ries: 
• Mild : For example, an AE  which is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: For example, an AE which is sufficiently discomforting to interfere with 
normal everyday activities . 
• Severe: For example, an AE which is incapacitating and prevents normal everyday 
activities.   
Worsening of a sign or symptom of the condition under treatment  will be recorded as AE and 
if this worsening  matches  any criterion for an “SAE”, it must be recor ded as such ( see S ection 
11.1.2).  
Examples of AEs include one of the following or a combination of two or more of these 
factors:  
• A new sign, symptom, illness, or syndrome.  
• Worsening of a concomitant or pre -existing condition. 
• An effect of the I MP or concomitant medication . 
• An effect of the IMD , if applicable  
• An effect of an invasive procedure required by the protocol.  
• An accident or injury.  
AEs can be categorized as “non -serious” and “serious” ( see S ection  11.1.2).  
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions that 
require surgery. The condition for which the surgery is required i s an AE, if it occurs or is 
detected during the study period. Planned surgical measures and the condition(s) leading to these measures are not AEs, if the condition(s) was (were) known before the study period ( see 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 52 of 78   Section  9.1) and do not worsen during the study. In the latter case, the condition should be 
reported as medical history.  
 Serious adverse events 
An AE  is considered “serious” if, in the view of either the  investigator or sponsor, it results in 
any of the following outcomes : 
• Results in death. 
• Is life -threatening.  
“Life -threatening” means that the subject was at immediate risk of death at the time of 
the SAE; it does not refer to an SAE that hypothetically might have caused death if it 
was more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization. 
This means that hospital inpatient admission or prolongation of hospital stay were 
required for the treatment of the AE, or that they occurred as a consequence of the 
event.  
• Results in persistent or significant disability or incapacity.  
“Persistent or significant disability or incapacity” means a permanent or significant 
and substantial disruption of a person’s ability to carry out normal life functions”. 
• Is a congenital anomaly or birth defect.  
• Is an important medical event.  
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in situations where none of the outcomes listed above  
occurred.  
Important medical events that may not be immediately life -threatening or result in 
death or hospitalization but may jeopardize the subject or may require interventions to 
prevent one of the other outcomes listed in the definition above should al so usually be 
considered serious. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasia, or convulsions 
that do not result in inpatient hospitalization, or the development of dr ug dependency 
or drug abuse.  
A diagnosis of a second cancer during a treatment should be considered as medically 
important.  
The term “severe” is often used to describe the intensity (severity) of a specific event (as in mild, moderate, or severe myocardial  infarction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as “serious”, which is based on the outcome or action criteria usually associated with events that 
pose a threat to lif e or functioning. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 53 of 78   
 Alert terms and other reasons for expedited reporting to 
Pharmacovigilance 
No particular AEs are subject to reporting as alert terms in this study . 
For details on known adverse reactions see Ameluz® PI (28) and c orresponding IB . 
Although not regarded as an SAE, any pregnancy in a subject occurring during treatment with 
the investigational products  must be reported to the sponsor immediately. Information related 
to the pregnancy must be given on a “Pregnancy report form” that will be provided by the sponsor. This information must be provided regardless of the decision to withdraw the subject  
from the study or discontinue the treatment.  
 Investigational medicinal product complaints 
Complaints associated with the I MP quality must be reported to the sponsor. 
 Investigational medical device complaints  
All AEs  reported in previous studies  were not d irectly related to the PDT lamp e. g. BF-
RhodoLED® but rather  to the medication or PDT. Therefore, we do not expect any AE s 
affecting subjects or third persons (e.g. study personnel)  that relate directly to BF -
RhodoLED® XL also referred to as Adverse Devis e Effects (ADEs), provided that it is 
properly used as described in the user manual.  
Nevertheless , if occurring  ADEs as well as technical complaints associated with the medical 
device BF-RhodoLED® XL must be reported to the sponsor  and IRB (in cases of (U)SADEs)  
ADEs reported by the t reated subject must be reported via the eCRF.  
11.2 Period of AE collection  
Collection of AEs starts with signing the informed consent documents until the end of the 
study. AEs will be discriminated as  pre-treatment adverse events  (PTAEs) and TEAEs.  
• AEs developing between signing the ICF and IMP application at Visit 2 will be 
considered  as PTAEs  and documented as an AE.  
• TEAEs are defined as all AEs or SAEs with onset or worsening after treatment with 
IMP up to Visit 5  
• If the investigator detect s an SAE in a subject after end of study, and considers the 
event possibly related to prior study treatment or procedures, he /she should report this 
event to the pharmacovigilance department of the sponsor (see S ection  11.3.1).  
11.3 Documentation and reporting of adverse events by investigator  
All AEs  as well as any SAE that occur throughout the study must be documented in 
accordance with the instructions for the completion of (S)AE reports in clinical studies. If 
possible, AEs should be assigned to be either unrelated (corresponding to unrelated or 
unlikely related) or related (corresponding to probably, possibly or definitely rel ated)  to the 
IMP or the IMD , or both, as this will be important for evaluation of the safety of BF -200 ALA 
or the PDT lamp. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 54 of 78   The following approach will be taken for documentation:  
• All AEs  during the study  (whether serious or non- serious ) must be documented. 
• If the severity category of an AE changes, the date of change and the new severity 
category must be documented.   
• If the AE  is serious ( see Section  11.1.2), the investigator must complete, in addition to 
the “Adverse Event” page in the eCRF, a “Serious Adverse Event/Expedited Report 
from a Clinical Trial for Combination products ” (SAE report ) form at the time the  
investigator became aware o f the SAE. This form must be marked as “initial” and be 
sent immediately (within 24  h) to the sponsor’s Pharmacovigilance department by 
email or fax (according to Biofrontera’s Standard Operating Procedure (SOP)). SAEs must be identified as such in eCRF by  stating the applicable SAE criteria that were 
met. 
• When a “significant overdose” of I MP occurs without an AE or in other situations 
where the sponsor requires an expedited report without an AE ( see S ection  11.1.3), 
this information should be provided by the investigator via the  “SAE  report ” form. It 
should be clearly stated that no AE was observed. In this case, there is no need to complete the “Advers e Event” page in the eCRF.  
• The following details regarding AEs are required:  
- confirmed medical diagnosis  or symptoms (if applicable)  
- location ( treatment area (s))  
- category : general, application site skin reaction , application site discomfort or 
new lesion  
- time frame (by providing start/stop date and time)  
- severity  and date of change of the  respective s everity  category if applicable 
(see S ection  11.1.1) . On the first day  of AE occurrence only the maximum 
severity has to be documented.  
- outcome ( recovered/resolved, recovering/reso lving; recovering with sequelae , 
not recovered/not resolved, fatal, unknown)  
- action taken (with reference to concomitant medications/treatments ) 
- seriousness criteria (if applicable), and  
- if the AE is related to I MP only, IMD  only, or both ( cannot be ambiguously 
assigned to one of both) .  
• For new lesions : inside or in close proximity (< 10 cm distance) to the treatment field  
• The causality/relatedness of AEs has to be assessed:  
- UNRELATED: AEs that are judged to be clearly and incontrovertibly due to a 
cause other than the I MP/IMD  and study procedure ( concomitant disease  etc.).  
- UNLIKELY RELATED: the temporal seq uence is atypical, and the AE does 
not follow a known pattern of response to I MP/IMD  another causative factor is 
present but causal role of the study drug cannot be excluded. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 55 of 78   - POSSIBLY RELATED : either an event that is temporally associated with the 
use of t he IMP/IMD  or a known pharmacological effect/associated reaction, 
which is also recognized with another concomitant therapy/ disease or other 
external cause.  
- PROBABLY RELATED : appropriate temporal association, known 
pharmacological effect, recognized to be an associated I MP/IMD  reaction and 
for which no other possible cause is evident. 
- DEFINITELY RELATED : the reaction has occurred with this I MP/IMD  
previously (i.e. positive re -challenge) and there is an appropriate temporal 
relationship between therapy and r eaction; and the reaction follows a known or 
expected response pattern to the suspected drug.  
The investigator should use medical judgment to determine whether he/she assumes a 
reasonable causal relationship, including into his/her evaluation all relevant factors and 
factual evidence such as  
- temporal course and latency  
- results from re -challenge  
- pattern of the reaction  
- known pharmacological properties of the product  
- and alternative explanations (e.g. other drugs, medical history, concomitant 
diseases).  
Every  attempt should be made to describe the AE in terms of a diagnosis. If a clear diagnosis 
has been made, individual signs and symptoms will not be recorded as separate AEs unless 
they represent atypical or extreme manifestations of the diagnosis, in which c ase they should 
be documented as separate events. In the case of SAEs or SARs, respectively, component signs and symptoms may be recorded in addition to a diagnosis if they further clarify the 
clinical picture. If a clear diagnosis cannot be established, e ach sign and symptom must be 
recorded individually. 
All subjects who have AEs, whether considered associated with the use of the I MP and/or the 
IMD  or not, should be monitored to determine the outcome. The clinical course of the AE will 
be followed up according to standard of care , even after the end of the study , until a 
satisfactory explanation is found or  the investigator considers it medically justifiable to 
terminate the follow -up. Should the AE result in death, a full pathologist’s report should be 
supplied, if possible. 
 Immediate reporting  
11.3.1.1 Reporting of SAEs  to sponsor  
SAEs observed throughout the study  must be documented on a n “SAE report” form  in 
accordance with instructions for completing the “SAE report” form . This form and the 
instructions will be provided in the investigator file and must be completed and supplied 
immediately (within 24 h) to the sponsor (21CFR§ 312.32, 21CFR§ 312.64). 
Clinical Study 
Protocol
 
 
2
1
-
Apr
-
202
2
 
ALA
-
AK
-
CT01
8
 
 
 
Amended 
Version 
3
.0
 
 
 
Biofrontera Bioscience GmbH 
–
 
Confidential
 
 
page 
56
 
of 
78
 
 
Any SAE that occurs 
throughout the study
, whether or not related to the IMP or the medical 
device, must be repo
rted by the investigator within 
24
 
h by fax, or by e
-
mail, to the following
 
contact data
:
 
Email: 
 
Fax
: 
 
 
The initial report must be as complete as possible, including details of the current 
disease
 
and 
(serious) AE, and an assessment of the causal relationship between the event and the IMP or 
IMD
 
or study procedures.
 
Information not available at the time of the initial report (e.g. an end date for the AE or 
laboratory values received after the report
) must be documented on a
n “SAE report” form
, 
with the box “Follow
-
up”
/”Final report”
.
 
The instructions for completing the 
“SAE report” form
 
give more detailed guidance on the 
reporting of SAEs, and AEs initially reported as non
-
serious that become serious
. In the latter 
situation, when a non
-
serious event becomes serious, details must be forwarded immediately
 
(within 24
 
h)
 
to the sponsor on a
n “SAE report” form
.
 
Note
:
 
For regulatory reporting purposes, events which are assessed by the sponsor as 
“unrelated” or 
“unlikely related” to the study medication will be considered as having no reasonable causal 
relation and will not be reported on an expedited basis.
 
Events assessed by the sponsor as “possibly, probably or definitely related” will be consid
ered 
as having a plausible causal relation to the study medication and will be reported if they are 
also considered unexpected and serious.
 
The sponsor will ensure that all legal reporting requirements to the competent authorities and 
the IRB(s) are met
 
(s
ee 
Section
 
11.4.2
)
.
 
11.3.1.2
 
Reporting of 
pregnancies
 
to spon
sor
 
Pregnancies occurring during a subject's participation in the study, although not typically 
considered SAEs, must be notified to the sponsor within the same timelines as an SAE (within 
24
 
h after becoming aware of the pregnancy) on a pregnancy notification form. Further 
treatment will be addressed on a case
-
by
-
case basis with the treating physici
an and the 
investigator.
 
Any pregnancy should be followed up until completion. If relevant, the development of the 
newborn will be monitored for an appropriate time post
-
delivery.
 
The 
p
harmacovigilance
 
department of the sponsor or designee has to be notifi
ed by fax or e
-
mail.
 
11.3.1.3
 
Reporting of USADEs to the 
sponsor
 
and to 
IRB
 
Events which can be clearly assigned to the 
IMD
 
and which are assessed by the investigator 
as “possibly, probably or definitely related” to the 
IMD
 
and which are both serious and 
unanticipa
ted will be considered as unanticipated 
serious 
adverse device effect (USADE). A 
report of any 
USADE
 
occurring during an investigation shall be submitted to the reviewing 

Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 57 of 78   IRB and the sponsor within 10 working days after the investigator first learns of the  effect (21 
CFR §812.150). 
In case a serious and unexpected event cannot  be clearly assigned to the IMD , it should be 
treated as an SAE ( see Section  11.1.2).  
Note: Reporting of USADEs to the sponsor is equal to SAE reporting described in Section  
11.3.1.1. 
11.3.1.4 Expedited r eporting of adverse events to IRB  
The investigator will promptly forward IND safety reports received from sponsor (see S ection  
11.4.2) and report all unanticipated problems involving risk to human subjects or others, and 
changes in the research activity to the IRB.  The sponsor may  submit IND safety reports 
directly to the IRB on the investigator’s behalf . Please refer to section 11.4.2. 
 Unblinding  
This is an open- label study, i.e., unblinding is not applicable . 
11.4 Documentation and reporting of adverse events by sponsor  
 Determination of expectedness, Reference Safety Information 
Expectedness of serious AEs will be determined by the sponsor according to the designated 
Reference Safety Information (RSI). Any updates or substantial amendments will be 
considered accordingly. The RSI for the investigational products will be included in the 
current IB.  
Unexpected: An AE or suspected adverse reaction is considered unexpected if it is not listed in the RSI or is not listed with the specificity or severity that has been observed. Unexpected, 
as used in this definition, also refers to AE s or suspected adverse reactions that are mentioned 
in the RSI as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug 
under investigation. 
 Expedited r eporting of adverse e vents to competent a uthorities and 
investigators 
The sponsor will report all serious and unexpected AEs , which are judged by the sponsor as 
having a reasonable suspected causal relationship ( unexpected serious suspected adverse 
reaction) as IND safety reports to the FDA and all participating investigators according to 
applicable law.  
The sponsor will also report USADEs to the FDA, all reviewing IRBs and to all investigators . 
The sponsor will submit IND safety reports directly to the IRB on the investigator’s behalf , 
e.g. when the investigator submits to a central IRB , to avoid multiple submissions to the IRB . 
In these cases, the investigator receives confirmation that the report has been sent to the IRB 
by the sponsor . 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 58 of 78   
 Periodic reporting of adverse events by sponsor  
A summary of all Investigational New Drug ( IND) safety reports will be included in the 
progress report submitted annually to the competent authorities within 60 days of the 
international anniversary date of the product (14 June, in agreement with authorities). The 
same report will also be submitted to the IRB(s) to ensure a continuing review of the project.  
11.4.3.1 Development safety update report ( DSUR)  
The sponsor will prepare and submit annual safety reports to competent authorities and 
concerned ethics committees.  
11.5 Continuous risk assessment  
The sponsor’s pharmacovigilance  department will apply appropriate monitoring measures to 
continuously survey the benefit risk ratio of the IMP, the IMD  and study procedures.  
12 WITHDRAWALS  
12.1 Withdrawal of subject s 
Subjects must be withdrawn from study  (i.e. from any further study procedure) for the 
following reasons:  
• At their own request (withdrawal of informed consent ) 
• If, in the investigator’s opinion, continuation in the study would be detrimental to the 
subject’s well -being  
• Upon sponsor request  
In all cases, the reason for and date of withdrawal must be documented. Subjects can withdraw consent at any time of the study without being obliged to specify a reason for their withdra wal. In case of an AE causing the withdrawal of consent , the AE has to be 
documented as cause of withdrawal.  
In case of withdrawal after  IMP administration the subject should be encouraged to come to a 
final visit for the conduct of safety assessments (phy sical examination, vital signs, safety 
laboratory including serum pregnancy test, if applicable, AEs and concomitant medication) as 
soon as possible. 
In case of withdrawal  before  IMP administration,  a final visit is not necessary. The subject 
will be consi dered as a drop -out. For subjects who are withdrawn before IMP administration 
only the date of i nformed c onsent, demographics and date and reason for withdrawal  and 
(S)AEs, if applicable,  have to be reported in the eCRF . The data will be  listed separately from 
data of treated subjects.   
A subject will be considered lost -to follow -up if he or she fails to return for scheduled visits 
and is unable to be contacted by the site. The investigator must make every effort to contact 
subjects lost to follow -up. Attempts to contact these subjects must be documented in the 
subject’s records (e.g. times and dates of attempted telephone contact, e -mails or copies of 
letters send to the subject). At least three attemp ts should be performed and documented. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 59 of 78   Discontinuation date is the date on which the investigator decides that no further attempt will 
be made to contact the subject and the subject is declared as lost -to follow -up. 
12.2 Replacement of subject s 
Subjects who discontinue will not be replaced.  
12.3 Withdrawal of samples  
Not applicab le.  
Clinical Study 
Protocol
 
 
2
1
-
Apr
-
202
2
 
ALA
-
AK
-
CT01
8
 
 
 
Amended 
Version 
3
.0
 
 
 
Biofrontera Bioscience GmbH 
–
 
Confidential
 
 
page 
60
 
of 
78
 
 
13
 
E
MERGENCY PROCEDURES
 
13.1
 
E
mergency sponsor 
contact
 
In emergency situations,
 
the investigator should contact the sponsor by phone at the number 
given 
below
, if that is regarded as necessary
:
 
 (
Biofrontera 
contact person in the USA
)
 
13.2
 
E
mergency identification of investigational medicinal products
 
I
n this open
-
label study, all eligible subjects will receive one active treatment. For this reason, 
special emergency identification procedures are not applicable for
 
this trial
.
 
13.3
 
E
mergency treatment
 
T
here is no substance
-
specific treatment for adverse reactions. 
For treatment of 
PDT 
associated 
pain and discomfort
 
please see 
S
ection 
9.2
.
 
During and after a subject’s participation in the trial, the investigator or institution should 
ensure that adequate medical care is provided to a subject for any AEs, including 
clinically 
si
gnificant 
laboratory values, related to the trial. The investigator or institution should inform 
a subject when medical care is needed for intercurrent 
disease
(es) of which the investigator 
becomes aware.
 
 
 

Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 61 of 78   14 STATISTICAL PROCEDURE S 
14.1 General considerations  
The principal features of the statistical analysis are described in this section. Technical details 
of the statistical analyses will be specified in a statistical analysis plan (SAP). The SAP will 
be finalized prior to the First -subject -first-visit for the  final analysis  of the study . The 
recommendations of the ICH E9 ‘Note for Guidance on Statistical Principles for Clinical Trials’ including the addendum R1 to ICH E9 will be taken into account. 
Unless otherwise stated, continuous data will be summarized by  means of descriptive 
statistics, i.e. number of subjects, mean, standard deviation (SD), median, quartiles and range 
(minimum and maximum). Categorical variables will be summarized by absolute and relative 
frequencies (percentages) of subjects by category . Missing values will not be included in the 
calculation of percentages.  
Eligible s ubjects who withdraw from study participation before IMP administration will be 
considered as dropouts . 
The demographic data from screening failures  and dropouts prior to IMP administration are 
entered into the clinical database and will not be passed through the data cleaning process. Their data are listed separately from data of treated subjects.  
Statistical analyses will be conducted using SAS version 9.4 or higher (SAS Institute, 2010).  
14.2 Analysis variables  
Study  objective 
The objective of the study is to evaluate the safety and tolerability of BF -200 ALA PDT, 
utilizing BF -RhodoLED® XL illumination, in the treatment of mild to severe AK on the face 
and scalp in an expanded field -directed treatment.  
The endpoints  of the study  are: 
• Frequency and severity of adverse events (AEs), serious AEs (SAEs), and treatment -
emergent adverse events  (TEAEs) . TEAEs are defined as all AEs with onset or 
worsening after treatment with IMP  up to Visit 5  
• Duration of TEAEs including the breakdown of severity category (mild, moderate, 
severe)  
• Assessment of new lesions (AK, NMSC such as BCC, SCC or Bowens disease, and melanoma) if they occur inside the treatment field  
• Assessment of new lesions (AK, NMSC such as BCC, SCC or Bowens disease , and 
melanoma) if they occur around the treatment field at a distance of < 10 cm  
• Application site skin reactions during and post PDT , assessed by the investigator  
• Application site discomfort during and post PDT , reported by the subject s 
• Application site pain during illumination, as assessed  by the subjects using  an 11- point 
numeric rating scale  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 62 of 78   • Changes in vital signs  
• Safet y laboratory data  
• Physical examination data  
• Neurological assessments  
14.3 Analysis sets  
Any decision for exclusion of individual subjects from an analysis population will be made 
before database lock in a data review meeting . Documentation concerning which subj ects are 
to be excluded from an analysis population will be prepared and reported, i.e., as data review 
minutes.  
• Consented set: All subjects who provided informed consent to participate in the study.  
• Safety analysis set (SAF): This set will include all subjects who undergo at least one 
of the following treatment procedures: preparation of the treatment field, application 
of BF -200 ALA, or illumination. The SAF is the analysis set for all safety analyses.  
14.4 Statistical methods  
The planned analyses are of ex ploratory nature without any formal statistical hypotheses. All 
measured variables and derived parameters of subjects who are treated will be listed and, if 
appropriate, tabulated in summaries. For categorical variables, frequency counts and percentages wi ll be used to summarize the results. Missing values will not be included in the 
calculation of percentages.  
Descriptive statistics of continuous variables will be provided including number of observations, arithmetic mean, standard deviation (SD), median, quartiles  as well as minimum 
and maximum.  
 Disposition of subjects  and exposure  
Descriptive analysis of subject s will be presented overall  and per study site.  
The number of subjects consented, treated, completed the study , prematurely discontinued 
from the  study  (with reason) and the number of screening failures will be displayed.   
Details of IMP administration and PDT procedure will be tabulated . 
 Demographics and background characteristics 
All variables concerning demographic and background characteristics will be summar ized to 
describe the study population. D ata will be presented for all subject s in the SAF. 
Concomitant medications will be coded according to Anatomical Therapeutic Chemical 
Classification System (ATC) and number and frequency  of subjects with previous or 
concomitant medication will be summarized.  
 Evaluation of the Safety  Endpoint s 
Safety analyses  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 63 of 78   All safety endpoints will be analyzed descriptively and in an exploratory way. These safety 
analyses will be performed  for the safet y set.  Selected s afety analyses will be conducted 
overall and stratified by age groups, sex, skin type, and treatment area.  
AEs will be coded according to the latest Medical Dictionary for Regulatory Activities (MedDRA) version available at the day of data base closure. The analysis will focus on the 
TEAEs. TEAEs will be summarized and tabulated according to primary system organ class 
and preferred term. TEAEs leading to death and TEAEs resulting in discontinuation of study 
will be tabulated using frequency tables.  
The mean total duration of TEAEs including the breakdown of severity category (mild . 
moderate, severe) will be presented overall and by treatment area.  
A listing of subject s with AEs will be provided for  all subjects  in the SAF . 
The frequency of application site  skin reactions and of application site  discomfort will be 
presented overall , and  per treatment area. The mean pain score (NRS -11) and the respective 
confidence intervals (CIs) , and the range  will be presented overall and by treatment area.  
All laboratory values will be classified as normal or abnormal according to the laboratory’s 
normal ranges and indicated as clinically significant or non- clinically significant by the 
investigator. Frequency tables for clinically significant findings will be provided. Laboratory 
values that are out of range and considered clinically significant will be additionally  
documented in the medical history (Visit 1) or as AEs ( 28 days  after the  PDT, Visit 5) and 
listed as such.  
The analyses of variables for vit al signs will focus on  
A) the evaluation of the change from baseline (Visit 2 , first measurement after the su bject 
arrived at the site ) to values on subsequent clinical visits  and 
B) The evaluation of the change  on Visit 2 f rom baseline (first measurement after the 
subject arrived at the site)  to values obtained prior and after illumination (until 60 min 
post illumination ). 
Descriptive analysis (number of subjects, mean, median and SD, minimum, maximum) of the time course and of changes from baseline to post base line time points will be presented.  
Physical examinations will include the following body systems: head , neck, skin, l ymph 
nodes, thorax including heart and lung , abdomen, and musculoskeletal, peripheral vascular 
and nervous system . 
Abnormal findings that are considered clinically significant will be additionally documented 
in the medical history (Visit 1) or as AEs at Visit 5 and listed as such.  
In addition, neurological assessments  will be performed at  Visit 1,  and at Visit 2  prior to PDT 
and 60 min after  end of illumination . 
Abnormal findings that are considered clinically significant will be additionally  documented 
in the medical history (Visit 1) or as AEs at Visit 2 and listed as such . 
Details of further analyses will be specified in the statistical an alysis plan ( SAP).   
 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 64 of 78   14.5 Handling of missing data  
Missing data of safety variables will not be replaced. Further details on the handling of 
missing data will be specified in the SAP.  
14.6 Interim analysis  
No formal interim analysis will be performed.   
14.7 Sample size justification  
No sample size calculation was conducted.  
14.8 Major Protocol Deviations  
Not applicable . No per protocol set is defined in this study.   
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 65 of 78   15 ETHICAL AND LEGAL ASPECTS  
15.1 Good clinical practice  
This study is to be conducted according to globally accepted standards of GCP (as defined in 
the ICH E6 (R2) Guideline for GCP), in agreement with the Declaration of Helsinki in its 
current version  and in keeping with local regulations. 
15.2 Delegation of investigator duties  
The investigator should ensure that all persons contributing to  the trial are adequately 
qualified, informed about the protocol, any amendments to the protocol, the study treatments, 
and their trial- related duties and functions.  
The investigator should immediately report any changes in study personnel  to the sponsor . 
Any regulatory requirement regarding a change in site personnel has to be met.  Besides that, 
the investigator should maintain a list of subinvestigators and other appropriately qualified persons to whom they have  delegated significant tria l-related duties.  
If required by local regulations, t he investigator should designate a deputy investigator with 
appropriate qualifications being able to fully replace the investigator in cases of absence.  
15.3 Subject  information , informed consent  and HIPAA fo rm 
Every trial participant will receive a complete and comprehensive explanation of the 
significance, nature, extent, and possible risks of the trial. To this end, a detailed, written subject information sheet will be made available. In addition, a n invest igator/subinvestigator 
will carry out an oral information session during which the subjects will be given ample time 
and opportunity to clarify remaining questions. 
Afterwards, the subject or their legal representative and the investigator /subinvestigator  will 
sign the informed consent  form  (ICF). To grant direct access to the subject's original medical 
records for verification of clinical trial procedures and/or data, without violating the 
confidentiality of the subject, the subject/legal representative will also sign an agreement. Depending on the local legal requirements this agreement can be part of the ICF or a separate 
form, such as the HIPAA form . The original signed ICF and, if applicable, HIPAA forms  will 
be archived in the ISF. The subject will receive a copy of these documents. The investigator 
will acknowledge instruction of every subject in accordance with the clinical  study protocol 
(CSP) and the existence of a signed consent and HIPAA form.  
Before valid consent has been obtained  the subject will not undergo any study related 
procedures. The investigator should inform the subject’s primary physician about the 
subject’s participation in the trial if the subject agrees to this.  
During the course of the trial, ICF may need to be updated and thus, requires re -consenting of 
subjects. T he investigator /subinvestigator will inform every active trial participant in a timely 
manner and obtain updated ICF in line with above mentioned obligations.  
15.4 Confidentiality  
To ensure confidentiality the subject’s data will be collected for the clinical data base and 
analysis in a strictly pseudonymous form, i.e. using a subject number instead of the subject’s 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 66 of 78   name.  The subject number will also be used  for SAE reporting purpos es. On s upporting 
documents of  an SAE report, such as hospital reports or laboratory  reports, the subject’s name 
and if required by regulations the physician’s name has to be obliterated.  
The investigator will maintain a personal subject identification lis t (subject numbers with the 
corresponding subject names) to enable records to be identified.  
Subject identity and personal data will be safeguarded according to national requirements on 
data protection. 
The sponsor adheres to data protection regulations.  
15.5 Protocol deviations  
Protocol deviation have to be documented and explained by the investigator and/or  the 
sponsor. Major protocol deviations have to be escalated to the sponsor. If there is a legal 
requirement, the investigator needs to report major protocol deviations to the responsible 
ethics comm ittee ( EC)/IRB.  
The sponsor is obliged to report serious breaches (severe violations of GCP regulations as 
well as all events that affect to a significant degree, the safety or physical or mental health of the subjects of the trial or the scientific value of the trial) to the IRB(s) and the applicable 
authorities.  
15.6 Protocol amendments  
The investigators cannot alter the protocol without the sponsor’s approval . If the sponsor 
amends the protocol all principal inves tigators need to agree to adhere to the amended 
protocol.  
In case of protocol changes that might affect the subjects ’ safety and well -being or the validity 
and integrity of the study data, the amendment is deemed substantial. Minor changes to the 
protocol , such as administrative changes, correction of typos  and inconsistencies  etc. stipulate 
a non- substantial amendment.  
15.7 Approval of the clinical study protocol and amendments 
Prior to the start of the study, the CSP , subject information leaflet and ICF, and any other 
appropriate documents will be submitted to the IRB(s) in charge. If applicable, the documents 
will also be submitted to the authorities, in accordance with local legal requirements.  
All ethical and legal requirements must be met before the sites  can start enrolling subjects.  
A protocol amendment has to be submitted to the IEC/IRB and, if required, to the regulatory 
authority(ies). In case of a non- substantial amendment these bodies only will be notified but 
they need to approve any substantial am endment to the protocol before it can be implemented. 
Amendments must be evaluated to determine whether the subject information leaflet and 
informed consent form should also be revised.  
The investigator must keep a record of all communication with the IRB( s) and, if applicable, 
between a Coordinating Investigator and the IRB(s). This also applies to any communication between the investigator (or Coordinating Investigator, if applicable) and the authorities.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 67 of 78   15.8 Ongoing information for ethics committee/instituti onal review board  
Periodic reports (e.g. annually) will be generated and submitted regarding to the requirements 
of the respective IRB or any appl icable law(s) for IRB continuing review.  
15.9 Closure of the study  
Upon study completion or premature termination, each investigational site will be closed.  
Completion or premature termination of the study will be reported to the regulatory agency and to the IRB if required by local regulation or by the IRB(s).  
Furthermore, the sponsor has the right to close a study s ite at any time. As far as possible, 
premature closure should occur after mutual consultation. 
Study materials must be returned, disposed of, or retained as directed by the sponsor. 
15.10  Record retention  
At the close -out visit the monitor will inform the sites about the required archiving period. 
The investigator must obtain approval in writing from the sponsor prior to destruction of any 
records and  must document any change of ownership. 
Within the United Stated of America the investigator has a legal obligatio n to retain records 
required to be maintained under 21 CFR §312.62 for a period of 2 years, following the date a 
marketing application is approved for the drug and the indication for which it is being 
approved. In case no application is to be filed or if t he application is not approved for such 
indication, records will be kept for two years after the investigation is discontinued and FDA 
is notified.  
This regulation applies to:  
• Adequate and accurate case histories that record all observations and other data  
pertinent to the investigation on each individual PDT such as:  
 
- Case report forms and supporting data.  
- Signed and dated consent forms. 
- Medical records including e.g. progress notes of the physician and nurse.  
- The case history of each subject shall document that informed consent was 
obtained prior to participation in the study.  
• Records documenting disposition of the I MP and IMD  (including dates, quantity, use 
and return to the sponsor) if the investigation is terminated, suspended, discontinued 
or co mpleted.  
15.11  Liability and insurance  
Liability and insurance provisions for subjects will be arranged according to legal 
requirements. If required by legal requirements, the subjects will receive a copy of the general 
conditions of insurance. Liability and ins urance provisions for investigators participating in 
this study will be defined in a separate agreement, if applicable.  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 68 of 78   15.12  Financial disclosure  
Prior to the start of the study, the investigator will disclose to the sponsor any proprietary or 
financial interes ts he or she might hold in the I MP, the IMD  or the sponsor company as 
outlined in the financial disclosure forms ( e.g. Form FDA 3454 or FDA 3455). By signing the 
financial disclosure form the investigator is also obliged to inform the sponsor about any changes up to one year after study completion/termination. 
Where required by regulation, the sponsor will also submit the financial arrangements for the 
study to the regulatory authorities and if applicable to the IRB(s). Similar information will be 
provided by each subinvestigator to whom the investigator delegates significant study -related 
responsibilities.  
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 69 of 78   16 QUALITY CONTROL , QUALITY ASSURANCE , AND 
INSPECTIONS   
Quality control mechanisms are implemented on a functional level and quality assurance 
audits will be done according to GCP (ICH Topic E6 (R2) GCP guideline ) and the applicable 
regulatory requirements. Direct access to the on -site study documentation and medical records 
must be ensured. 
16.1 Study monitoring and  source data verification  
Monitoring is the ac t of overseeing the progress of a clinical trial, and of ensuring that it is 
conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and the applicable regulatory requirement(s). T he frequency of monitoring and co- monitoring visits, 
and the degree of source data verification are defined in the monitoring plan. Monitoring will 
be done by on- site or remote visits . In addition to the monitoring visits, frequent 
communications (letter  or email , telephone, and fax) by the clinical monitor w ill ensure that 
the investigation is conducted according to protocol design and regulatory requirements.  
The results of monitoring visits will be documented in monitoring reports. Issues arising will be escalated and dealt with in a timely manner. The escalation process is defined in the 
respective SOPs of the sponsor or contract research organization  (CRO ), if applicable.  
Study closeout will be performed by the clinical monitor upon closure of the study.  
16.2 Site audits  
Audits can be conducted at any time during or after the trial to assure the validity and integrity of the study data , the protection of the right, safety and well -being of the subjects  and the 
adherence to the protocol, to ICH -GCP, ISO  14155 (if applicable)  and to the applicable legal 
requir ement s. On-site audits will be conducted by an independent auditor from the respective 
or the sponsor or delegate. Direct access to these documents must be guaranteed by the investigator, who must provide support at all times for these activities.  
16.3 Site Inspections  
Domestic and foreign r egulatory authority(ies) may conduct  an official review of documents, 
facilities, records, and any other resources that are deemed by the authority(ies) to be related 
to the clinical trial and that may be located at the site of the trial.  For this, the 
investigator/institution has to give access to all source documents, eCRFs, and other study 
documentation for an  inspection. The investigator should inform the sponsor as soon as 
possible about any announced inspection. Site personnel should f ully comply with inspection 
procedures . 
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 70 of 78   17 DOCUMENTATION AND US E OF STUDY FINDINGS  
17.1 Documentation of study findings  
This study will be performed using an eCRF. The investigator s and study site staff will 
receive system documentation, training, and support for the use of the eCRF. 
All protocol -requir ed information collected during the study must be entered by the 
investigator, or a designated representative, in the eCRF as soon as possible, preferably on the 
same day that a study subject is seen for an examination, treatment, or any other study 
proced ure. Any outstanding entries must be completed immediately after the final 
examination. An explanation should be given for all missing data. All data entry, modification or deletion will be recorded automatically in an electronic audit trail, indicating th e individual 
subject, original value, the new value, the reason for change, who made the change, and when the change was made. All data changes will be clearly indicated with a means to locate prior 
values. The system will be secured to prevent unauthorize d access to the data or the system. 
This will include the requirement for a user identification and password to enter or change data. The investigator will maintain a list of individuals who are authorized to enter or correct 
data and their system identification.  
All electronic data entered by the site (including an electronic audit trail) as well as computer hardware and software (for accessing the data) will be maintained or made available at the site 
in compliance with applicable record retention regulat ions. The computerized system is able 
to generate accurate and complete copies of records in both human -readable and electronic 
form for inspection, review, and copying by regulatory authorities, the IRB(s), and auditors 
authorized by the sponsor. 
A source  data location list will be prepared and updated during the study. It will specify which 
types of source data are available and where they are stored (e. g. electronic or paper subject 
files etc.), and which data may be entered directly into the eCRF. This  list will be filed in both 
the TMF  and the investigator study file and updated as necessary. The sites can establish 
appropriate work sheets or record the source data directly in subjects’ notes. Source data 
entries have to be signed and dated by the resp ective investigator or delegated person in 
compliance with the delegation log in which responsibilities and duties of the study performance are laid down. In addition, all changes and additional entries have to be made 
visible and signed and dated by the r espective study team member.  
The investigator, or designated subinvestigator, following review of the data in the eCRF, will 
confirm the validity of each subject’s data by electronic signature. The sponsor will retain the 
original eCRF data and audit trail. A copy of all eCRFs completed by the site will be provided 
to the concerned investigator. 
17.2 Use of study findings  
All information concerning the product as well as any matter concerning the operation of the 
sponsor, such as clinical indications for the dru g or medical device, the drug formula, methods 
of manufacture and other scientific data relating to it, that have been provided by the sponsor and are unpublished, are confidential and must remain the sole property of the sponsor. The 
investigator will agr ee to use the information only for the purposes of carrying out this study 
and for no other purpose unless prior written permission from the sponsor is obtained. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 71 of 78   The sponsor has full ownership of the eCRFs completed as part of the study.  
By signing the CSP , the investigator agrees that the results of the study may be used for the 
purposes of national and international registration, publication, and information for medical 
and pharmaceutical professionals. The authorities will be notified of the investigator ’s name, 
address, qualifications, and extent of involvement. 
The sponsor will ensure that a final report on the study is prepared.  
As required by local regulation or by the IRB(s), a summary of the clinical study will be 
submitted by the sponsor to the reg ulatory authorities and by the sponsor or investigator to the 
IRB(s).  
The Coordinating Investigator of a multi- center trial or the Investigator in a  single -center trial 
will be required to sign a statement in the clinical study report in which he or she confirms 
that, to the best of his or her knowledge, it accurately describes the conduct and results of the 
study.  
All materials, documents, and information supplied by the sponsor to the investigator, and all 
materials, documents, and information prepared or developed in the course of the study to be 
performed under this protocol, shall be the sole and exclusive property of the sponsor.  
Scientific p ublication of the study results may be planned mutually between the sponsor and 
the Investigator. Details of t he publication policy will be specified in the investigator 
contracts.  
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 72 of 78   18   References  
1. Czarnecki D, Meehan CJ, Bruce F, Culjak G. The majority of cutaneous squamous cell 
carcinomas arise in actinic keratoses. J Cutan.Med Surg. 2002;6(3):207–9. PubMed PMID:  11951126. 
2. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am. Acad. Dermatol 2000;42(1 Pt 2):4–7. PubMed PMID:  10607349.  
3. Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) -  short version, part 2: 
epidemiology, surgical and systemic treatment of cSCC, follow -up, prevention and 
occupational disease. Journal der Deutschen Dermatologischen Gesellschaft  = Journal of 
the German Society of Dermatology : JDDG 2020;18(4):400–13. doi: 10.1111/ddg.14072. PubMed PMID:  32247292. 
4. Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, et al. Guidelines of care for the management of actinic ker atosis. J Am Acad Dermatol 2021. 
doi: 10.1016/j.jaad.2021.02.082. PubMed PMID:  33820677. 
5. Glogau RG. The risk of progression to invasive disease. J Am. Acad. Dermatol 2000;42(1 Pt 2):23–4. PubMed PMID:  10607353.  
6. Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol 2016. doi:  10.1111/jdv.13626. 
7. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic kerat osis to 
squamous cell carcinoma. Dermatol Surg. 2007;33(9):1099–101. PubMed PMID:  17760601. 
8. Fernandez -Figueras MT, Carrato C, Saenz X, Puig L, Musulen E, Ferrandiz C, et al. 
Actinic keratosis with atypical basal cells (AK I) is the most common lesion as sociated 
with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015;29(5):991–7. doi:  10.1111/jdv.12848. PubMed PMID:  25428612.  
9. Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence - and consensus -based (S3) Guidelines for the Treatment of Actinic Keratosis -  
International League of Dermatological Societies in cooperation with the European 
Dermatology Forum -  Short version. J Eur Acad Dermatol Venereol 2015;29(11):2069–
79. doi:  10.1111/jdv.13180. 
10. Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad 
Dermatol Venereol 2017;31 Suppl 2:8–11. doi:  10.1111/jdv.14092. PubMed 
PMID:  28263021. 
11. Berman B, Bienstock L, Kuritzky L, Mayeaux,E.J.,Jr., Tyring SK. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam.Pract. 2006;55(5):suppl -8. PubMed PMID:  16672155.  
12. Calzavara- Pinton P, Hædersdal M, Barber K, Basset -Seguin N, Del Pino Flores ME, 
Foley P, et al. Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDT. J Cutan Med Surg 2017:1203475417702994. 
doi: 10.1177/1203475417702994. PubMed PMID:  28406719. 
13. Jetter N, Chandan N, Wang S, Tsoukas M. Field Cancerization Therapies for 
Management of Acti nic Keratosis: A Narrative Review. Am J Clin Dermatol 
2018;19(4):543–57. doi:  10.1007/s40257- 018-0348- 7. PubMed PMID:  29582369. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 73 of 78   14. Berker D de, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British 
Association of Dermatologists' guidelines for the ca re of patients with actinic keratosis 
2017. Br J Dermatol 2017;176(1):20–43. doi:  10.1111/bjd.15107. PubMed 
PMID:  28098380. 
15. Maisch T, Santarelli F, Schreml S, Babilas P, Szeimies RM. Fluorescence induction of 
protoporphyrin IX by a new 5- aminolevulinic  acid nanoemulsion used for photodynamic 
therapy in a full -thickness ex vivo skin model. Exp Dermatol 2010;19(8):e302- e305. 
PubMed PMID:  19845760. 
16. Schmitz L, Novak B, Höh AK, Lübbert H, Dirschka T. Epidermal penetration and 
protoporphyrin IX formation of two different 5 -aminolevulinic acid formulations in ex 
vivo human skin. Photodiagnosis Photodyn Ther 2016;14:40–6. doi: 10.1016/j.pdpdt.2015.11.004. PubMed PMID:  26607556. 
17. Rossi A, v. Garelli, Pranteda G, Cardone M, Anzalone A, Fortuna MC, et al. Dermoscopy and methyl aminolevulinate: A study for detection and evaluation of field 
cancerization. Journal of photochemistry and photobiology. B, Biology 2016;162:72–6. doi: 10.1016/j.jphotobiol.2016.06.028. PubMed PMID:  27344021.  
18. Statistical/Clinical R eview and Evaluation.: Addendum (application number: 21-  005): 
Food and Drug Administration; Center for Drug Evaluation and Research (CDER); 1999. 
19. Aldara®. Full Prescribing Information Aldara® Cream 5%; 2010.  
20. Full prescribing information for TOLAK CREAM: TOLAK (fluorouracil) Cream, 4%, 
for topical use: HILL DERMACEUTICALS, INC.; 2020. 
21. Braathen LR, Szeimies RM, Basset -Seguin N, Bissonnette R, Foley P, Pariser D, et al. 
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an 
international consensus. J Am Acad Dermatol 2007;56(1):125–43. PubMed PMID:  17190630. 
22. Vegter S, Tolley K. A Network Meta -Analysis of the Relative Efficacy of Treatments for 
Actinic Keratosis of the Face or Scalp in Europe. PloS one 2014;9(6):e96829. doi: 10.1371/journal.pone.0096829. PubMed PMID:  24892649. 
23. Dirschka T, Radny P, Dominicus R, Mensing H, Bruning H, Jenne L, et al. Photodynamic therapy with BF -200 ALA for the treatment of actinic keratosis: results of 
a multicentre, randomized, observer -blind phase III study in comparison with a registered 
methyl- 5-aminolaevulinate cream and placebo. Br J Dermatol 2012;166(1):137–46. 
PubMed PMID:  21910711. 
24. Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn- Senftleben G, et al. 
Photodynam ic therapy with BF -200 ALA for the treatment of actinic keratosis: results of 
a prospective, randomized, double -blind, placebo- controlled phase III study. Br J 
Dermatol 2010;163(2):386–94. PubMed PMID:  20518784. 
25. Reinhold U, Dirschka T, Ostendorf R, Asc hoff R, Berking C, Philipp- Dormston WG, et 
al. A randomized, double -blind, phase III, multicentre study to evaluate the safety and 
efficacy of BF -200 ALA (Ameluz((R)) ) vs. placebo in the field- directed treatment of 
mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF -
RhodoLED((R)) lamp. Br J Dermatol 2016;175(4):696–705. doi:  10.1111/bjd.14498. 
PubMed PMID:  26921093. 
26. EudraCT Number 2017 -000486- 72 - Clinical trial results -  EU Clinical Trials Register 
[Internet] [cited 20 19 Dec 2]. Available from: 
https://www.fda.gov/media/70858/download. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 74 of 78   27. Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-
photodynamic therapy of skin disease. J Am. Acad. Dermatol 2009;61(6):1033–43. 
PubMed PMID:  1992592 9. 
28. Full Prescribing Information Ameluz® (aminolevulinic acid hydrochloride) gel 10%: 
Ameluz: Biofrontera Pharma GmbH; 2021.  
29. Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, et al. Guidelines for practical use of MAL -PDT in non- melanom a skin cancer. J Eur Acad Dermatol Venereol 
2010;24(5):505–12. doi:  10.1111/j.1468- 3083.2009.03430.x. PubMed PMID:  19807828. 
30. Philipp -Dormston W. Professionelles Schmerzmanagement bei der 
PhotodynamischenTherapie. Ästhetische Dermatologie 2012(3):52 Ger man.  
31. Wang B, Shi L, Zhang YF, Zhou Q, Zheng J, Szeimies RM, et al. Gain with no pain?: Pain management in dermatological photodynamic therapy. Br J Dermatol 2017;177(3):656–65. doi:  10.1111/bjd.15344. PubMed PMID:  28122416.  
32. Fitzpatrick TB. The validity and practicality of sun -reactive skin types I through VI. 
Arch.Dermatol 1988;124(6):869–71. PubMed PMID:  3377516.  
33. Olsen EA, Abernethy ML, Kulp- Shorten C, Callen JP, Glazer SD, Huntley A, et al. A 
double -blind, vehicle -controlled study evaluating masoprocol cream in the treatment of 
actinic keratoses on the head and neck. J Am Acad Dermatol 1991;24(5 Pt 1):738–43. 
PubMed PMID:  1869646. 
34. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;131(4):455–
64. PubMed PMID:  7947197. 
35. Schwartz RA. The actinic keratosis. A perspective and update. Dermatologic surgery : 
official publication for American Society for Dermatologic Surgery [et al.] 
1997;23(11):1009- 19; quiz 1020- 1. PubMed PMID:  9391557. 
36. Yantsos VA, Conrad N, Zabawski E, Cockerell CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin.Cutan.Med Surg. 1999;18(1):3–14. PubMed PMID:  10188837. 
 
 
 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 75 of 78   19 APPENDICES  
 
Appendix A:  Fitzpatrick’s Skin Type Test according to Fitzpatrick (1988)  
  
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 76 of 78   APPENDIX A  
Fitzpatrick´s Skin Type Test  
Fitzpatrick´s Skin Type according to Fitzpatrick , 1988 (32)  
 
Skin type is often categorized according to the Fitzpatrick skin type scale, which ranges from 
very fair (skin type  I) to very dark (skin type  VI). The 2 main factors that influence  the skin 
type are:  
• Genetic disposition. 
• Reaction to sun exposure and tanning habits.  
Skin type is determine d genetically and is one of the many aspects of a subject ´s overall 
appearance, which also includes color of eyes, hair, etc. The way the  skin reacts to sun 
exposure is another important factor in correctly assessing the skin type. Recent tanning (sun 
bathing, artificial tanning or tanning creams) have a major impact on the evaluation of skin 
color.  
Please use to following questionnaires to assess subject´s skin type.  
 
Genetic disposition  
Score  0 1 2 3 4 
What is the color of 
your eyes?  Light blue, Gray, Green
 Blue, Gray or Green  Blue Dark Brown  Brownish 
Black  
What is the natural 
color of your hair?  Sandy Red  Blond  Chestnut/ 
Dark Blond  Dark Brown  Black  
What is the color of 
your skin (non 
exposed areas)?  Reddish  Very Pale  Pale with 
Beige tint  Light Brown  Dark Brown  
Do you have freckles on unexposed areas?  Many  Several  Few Incidental  None 
Total score for genetic disposition: _____  
 
 
 
 
 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 77 of 78   Fitzpatrick’s Skin Type Test  
(cont.)  
 
 
Reaction to sun exposure  
 
Score  0 1 2 3 4 
What happens when you stay in the sun  
too long?  Painful 
redness, 
blistering, peeling  Blistering followed by 
peeling  Burns sometimes 
followed by peeling  Rare burns  Never had burns  
To what degree do 
you turn brown? Hardly or not at all  Light color tan Reasonable tan Tan very 
easy  Turn dark brown 
quickly  
Do you turn brown 
within several hours 
after sun exposure?  Never  Seldom  Sometimes  Often Always  
How does your face 
react to the sun?  Very 
sensitive  Sensitive  Normal  Very 
resistant  Never had a problem  
 
Total score for reaction to sun exposure: _____  
 
 
Tanning habits  
 
Score  0 1 2 3 4 
When did you last expose your body to sun (or artificial 
sunlamp/tanning cream)?  More than 
3 months 
ago 2-
3 months 
ago 1-2 months 
ago Less 
than a 
month 
ago Less than 
2 weeks ago  
Did you expose the area to 
be treated to the sun?  Never  Hardly 
ever Sometimes  Often Always  
 
Total score for tanning habits: _____  
 
 
Add up the total scores of each of the three sections for calculation of subject’s skin type 
score. 
Clinical Study Protocol   21-Apr-2022  
ALA- AK-CT01 8   Amended Version 3.0 
 
 
Biofrontera Bioscience GmbH – Confidential   page 78 of 78   Fitzpatrick skin type will be  assessed according to skin type score as follows:  
 
Skin Type Score  Fitzpatrick Skin Type  
0 – 7 I 
8 – 16 II 
17 – 24 III 
25 – 30 IV 
>30 V – VI 
 
 